beta

AMGN

Amgen Inc.

Amgn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-30-2018 after market close 07-26-2018 after market close 04-24-2018 after market close 02-01-2018 after market close 10-25-2017 after market close 07-25-2017 after market close 04-26-2017 after market close
Actual EPS 3.69 3.83 3.47 2.89 3.27 3.27 3.15
Consensus EPS 3.42 3.52 3.23 3.04 3.09 3.09 3.0
Estimated EPS 3.42 3.52 3.23 3.04 3.09 3.09 3.0
Number of Estimates 10 10 10 11 11 11 11
EPS Surprise $0.27 $0.31 $0.24 -$0.15 $0.18 $0.18 $0.15

Stats

Summary

Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

Market Cap: 142 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.amgen.com

Shares Outstanding: 726 Million

Float: 723 Million

Dividend: 5.28 (2.69%)

Beta: 1.472009

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 9.67 Million

Ethical Flags

Animal testing

Longest drawdown: 397 trading days

From: 2015-07-31 To: 2017-02-28

Lowest Point:

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

via: PR Newswire at 2018-12-10 16:41:00:000

THOUSAND OAKS, Calif. and SAN FRANCISCO , Dec. 10, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable… read more...

Challenges For Gilead's 2 New CEOs

via: SeekingAlpha at 2018-12-10 13:23:58:000

Introduction: Gilead ( GILD ) will have three CEO's in less than three months In January 2016, GILD announced that its long-serving CEO, John Martin, was being succeeded by GILD lifer John Milligan, with Dr. Martin moving up to the role of executive CEO. Following a multi-month search, GI… read more...

What One Sector Offers Safety As Markets Get Roiled?

via: SeekingAlpha at 2018-12-10 11:42:07:000

The sharp drop in stocks that rocked markets earlier this year, in February and March 2018, became a distant memory. Tax cuts and repatriation of foreign assets back to the U.S. supported the rise in stocks in the spring and summer. As investors now know, mere threats of the U.S.-China tarif… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus

via: SeekingAlpha at 2018-12-08 09:31:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr… read more...

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

via: PR Newswire at 2018-12-07 16:00:00:000

THOUSAND OAKS, Calif. , Dec. 7, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1 .45per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019 , to all stockholders of record as of the close o… read more...

BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%

via: SeekingAlpha at 2018-12-06 11:43:25:000

Ultra-thinly traded BeyondSpring ( BYSI +3.2% ) is up on almost double normal volume, albeit on turnover of only 12K shares, on the heels of its announcement of positive results evaluating lead candidate Plinabulin in patients receiving docetaxel chemotherapy. More news on: BeyondSprin… read more...

Spectrum Pharma's Rolontis on par with Amgen's Neulasta in late-stage breast cancer study

via: SeekingAlpha at 2018-12-06 10:41:45:000

Results from a Phase 3 clinical trial, RECOVER , evaluating Spectrum Pharmaceuticals' ( SPPI -2.4% ) ROLONTIS (eflapegrastim) for reducing the duration of severe neutropenia (low levels of a type of white blood cell called neutrophils) in breast cancer patients receiving chemo showed i… read more...

AbbVie: A Compelling Buy

via: SeekingAlpha at 2018-12-06 09:30:00:000

(Source: TheStreet ) Investment Thesis The biopharmaceutical company AbbVie Inc. ( ABBV ) has been one of the more controversial names in the large-cap health care space over the last year, with a number of strong arguments being made on both the bullish and the bearish sides. ABBV had be… read more...

Amgen Inc. (AMGN) Presents at 60th American Society of Hematology (ASH) Annual Meeting Presentation (Transcript)

via: SeekingAlpha at 2018-12-05 20:07:05:000

Amgen Inc. (AMGN) 60th American Society of Hematology Annual Meeting December 03, 2018 11:00 PM ET Executives Arvind Sood - VP, IR Dr. David Reese - Head of R&D Dr. Greg Friberg - VP, Global Development and Therapeutic Area Head for Oncology Dr. Max Topp - Head of Hematolog… read more...

Amgen Can Offer Total Returns Of Nearly 10% Per Year

via: SeekingAlpha at 2018-12-04 13:54:02:000

Written by Nate Parsh for Sure Dividend With just eight years of paying and raisings its dividend, Amgen ( AMGN ) is a relatively young dividend paying company. While it may lack the number years of dividend growth that some healthcare stocks can boast about, Amgen has increased its di… read more...

Amgen Can Offer Total Returns Of Nearly 10% Per Year

via: SeekingAlpha at 2018-12-04 13:54:02:000

Written by Nate Parsh for Sure Dividend With just eight years of paying and raisings its dividend, Amgen ( AMGN ) is a relatively young dividend paying company. While it may lack the number years of dividend growth that some healthcare stocks can boast about, Amgen has increased its di… read more...

Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model

via: SeekingAlpha at 2018-12-04 09:05:36:000

Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit… read more...

Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model

via: SeekingAlpha at 2018-12-04 09:05:36:000

Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit… read more...

Amgen's BiTE candidate AMG 420 shows positive action in early-stage blood cancer study but AMG 330 lags

via: SeekingAlpha at 2018-12-04 08:32:54:000

Results from the study evaluating a range of doses of Fast Track-tagged AMG 420 in patients with relapsed/refractory multiple myeloma who had received at least two prior lines of treatment showed a 31% (n=13/42) response rate, including seven complete responders. The response rate in patient… read more...

Amgen's BiTE candidate AMG 420 shows positive action in early-stage blood cancer study but AMG 330 lags

via: SeekingAlpha at 2018-12-04 08:32:54:000

Results from the study evaluating a range of doses of Fast Track-tagged AMG 420 in patients with relapsed/refractory multiple myeloma who had received at least two prior lines of treatment showed a 31% (n=13/42) response rate, including seven complete responders. The response rate in patient… read more...

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

via: PR Newswire at 2018-12-03 21:15:00:000

THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE ) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation stud… read more...

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

via: PR Newswire at 2018-12-03 21:15:00:000

THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE ) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation stud… read more...

Amgen To Present At The Citi Global Healthcare Conference

via: PR Newswire at 2018-12-03 16:00:00:000

THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday , Dec. 6, 2018, in New York City . Elliott M. Levy , M.D., senior vice president of Global Development at Amgen, will present… read more...

41 'Safer' Dividend Healthcare Pre-December WallStars From Dividend Dogcatcher

via: SeekingAlpha at 2018-12-03 13:45:10:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast Ten High Yield Top Healthcare 'Safer' Dividend Stocks to Net 12.6% to 26.75% Gains To November 2019 Four of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the t… read more...

Biohaven Pharma up 17% on positive data on migraine med Zydis

via: SeekingAlpha at 2018-12-03 12:05:58:000

Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...

EV Charging Gets $240M Push As Trump Threatens Cuts

via: SeekingAlpha at 2018-12-01 11:46:54:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. EV charging: Chevron (CVX) Technology Ventures and American Electric Power (AEP) were among the investors in a … read more...

EV Charging Gets $240M Push As Trump Threatens Cuts

via: SeekingAlpha at 2018-12-01 11:46:54:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. EV charging: Chevron (CVX) Technology Ventures and American Electric Power (AEP) were among the investors in a … read more...

Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY(TM) (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

via: PR Newswire at 2018-11-30 16:00:00:000

THOUSAND OAKS, Calif. and BRUSSELS , Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics… read more...

Synthorx Files Proposed Terms For U.S. IPO

via: SeekingAlpha at 2018-11-29 11:32:20:000

Quick Take Synthorx ( THOR ) intends to raise $100 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of biologic treatment candidates for cancers and autoimmune diseases. THOR wont enter Phase 1 trials for its lead… read more...

FDA Ad Com January 16 for Amgen's osteoporosis med romosozumab

via: SeekingAlpha at 2018-11-29 09:43:26:000

The FDA's Reproductive and Urologic Drugs Advisory Committee will meet on Wednesday, January 16, 2019, to review and discuss Amgen's ( AMGN -0.4% ) resubmitted marketing application seeking approval for romosozumab, branded as EVENITY, for the treatment of osteoporosis in postmenopausal … read more...

Amgen opts in on second cancer program with Nuevolution

via: SeekingAlpha at 2018-11-29 06:55:40:000

Nuevolution announces that collaboration partner Amgen (NASDAQ: AMGN ) has exercised its opt-in right to a second cancer program and will take over all further R&D costs. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen Inc. (AMGN) Management Presents at Evercore ISI Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-11-29 02:50:43:000

Amgen Inc. (AMGN) Evercore ISI Healthcare Conference Call November 28, 2018 11:00 ET Executives Elliott Levy - Senior Vice President, Global Development Arvind Sood - Head, Investor Relations David Meline - Chief Financial Officer Analysts Umer Raffat - Evercore ISI Pres… read more...

Amgen To Webcast Investor Call At ASH 2018

via: PR Newswire at 2018-11-28 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 28, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018 , at8 p.m. PT.David M. Reese, M.D., ex… read more...

Boehringer Ingelheim bails on biosimilars ex-U.S.

via: SeekingAlpha at 2018-11-28 11:45:19:000

Following Merck KGaA's ( OTCPK:MKGAF ) lead, Boehringer Ingelheim (BI) has decided to abandon biosimilars outside of the U.S. despite its Humira (adalimumab) biosimilar, Cyltezo, being approved in the EU since 2017. It says it will focus on commercializing Cyltezo in the U.S., approved by … read more...

Amgen Inc. (AMGN) Management Presents at Piper Jaffray Healthcare Conference Call (Transcript)

via: SeekingAlpha at 2018-11-28 04:14:16:000

Amgen Inc. (AMGN) Piper Jaffray Healthcare Conference Call November 27, 2018 08:30 ET Executives Elliott Levy - Senior Vice President, Global Development Arvind Sood - Head, Investor Relations Analysts David Amsellem - Piper Jaffray Presentation David Amsellem Okay,… read more...

Google asks for refund of campaign contribution to embattled Sen. Cindy Hyde-Smith

via: CNBC at 2018-11-26 17:28:00:000

No summary available. read more...

Google asks for refund of campaign contribution to embattled Sen. Cindy Hyde-Smith

via: CNBC at 2018-11-26 17:28:00:000

No summary available. read more...

Top Holdings Of Dividend ETFs (Part 2: The Top 10 By Sector)

via: SeekingAlpha at 2018-11-26 16:40:16:000

In Part 1 of this article , I presented a virtual portfolio of the top holdings of 47 dividend ETFs. Using a proportional scoring system that favors larger investments and larger ETFs, I calculate an aggregate score for each ticker in the top 25 holdings of the dividend ETFs. Sorting the aggr… read more...

Top Holdings Of Dividend ETFs (Part 2: The Top 10 By Sector)

via: SeekingAlpha at 2018-11-26 16:40:16:000

In Part 1 of this article , I presented a virtual portfolio of the top holdings of 47 dividend ETFs. Using a proportional scoring system that favors larger investments and larger ETFs, I calculate an aggregate score for each ticker in the top 25 holdings of the dividend ETFs. Sorting the aggr… read more...

Ignore Trader Noise, Buy QQQ Now

via: SeekingAlpha at 2018-11-26 16:02:47:000

Three months ago I was telling you to start selling stocks . By my 4th Quarter Macro And Market Outlook (Editor's Pick) in early October, I said this: "I am holding about 25% cash in portfolios because…risk is high." Over the past three weeks I have been scaling back into stocks... read more...

Ignore Trader Noise, Buy QQQ Now

via: SeekingAlpha at 2018-11-26 16:02:47:000

Three months ago I was telling you to start selling stocks . By my 4th Quarter Macro And Market Outlook (Editor's Pick) in early October, I said this: "I am holding about 25% cash in portfolios because…risk is high." Over the past three weeks I have been scaling back into stocks... read more...

Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences

via: PR Newswire at 2018-11-21 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday , Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018 ,… read more...

Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences

via: PR Newswire at 2018-11-21 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday , Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018 ,… read more...

Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences

via: PR Newswire at 2018-11-21 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday , Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018 ,… read more...

Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences

via: PR Newswire at 2018-11-21 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday , Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018 ,… read more...

AT&T, Leidos and Walmart ask Sen. Cindy Hyde-Smith for donations back because of hanging comments

via: CNBC at 2018-11-20 09:46:00:000

No summary available. read more...

European advisory group reverses position, now backs Amgen's Blincyto for type of ALL; shares up 1%

via: SeekingAlpha at 2018-11-16 10:21:42:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for Amgen's ( AMGN +0.6% ) BLINCYTO (blinatumomab) for the treatment ofadults with Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukemia (ALL)… read more...

European advisory group reverses position, now backs Amgen's Blincyto for type of ALL; shares up 1%

via: SeekingAlpha at 2018-11-16 10:21:42:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for Amgen's ( AMGN +0.6% ) BLINCYTO (blinatumomab) for the treatment ofadults with Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukemia (ALL)… read more...

European advisory group reverses position, now backs Amgen's Blincyto for type of ALL; shares up 1%

via: SeekingAlpha at 2018-11-16 10:21:42:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for Amgen's ( AMGN +0.6% ) BLINCYTO (blinatumomab) for the treatment ofadults with Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukemia (ALL)… read more...

European advisory group reverses position, now backs Amgen's Blincyto for type of ALL; shares up 1%

via: SeekingAlpha at 2018-11-16 10:21:42:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for Amgen's ( AMGN +0.6% ) BLINCYTO (blinatumomab) for the treatment ofadults with Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukemia (ALL)… read more...

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-11-16 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO (blinatumo… read more...

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-11-16 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO (blinatumo… read more...

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-11-16 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO (blinatumo… read more...

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-11-16 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO (blinatumo… read more...

Cancer Research Highlight: RedHill Biopharma Sets Up Continued Invasion Into Cancer

via: SeekingAlpha at 2018-11-15 10:56:21:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. RedHill Biopharma ( RDHL ) is … read more...

CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009

via: SeekingAlpha at 2018-11-15 10:17:24:000

Introduction Since first covering CytomX ( CTMX ) back in January , the company's stock has been on a wild ride while the company has made significant strides towards the validation of its game-changing 'probody' platform: Annotated 1-year chart created by the author. In my init… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

Biogen: Spinning Around Spinraza

via: SeekingAlpha at 2018-11-13 16:31:42:000

Biogen's ( BIIB ) stock was trading at around $300-$330 within the past month. Due to unimpressive growth opportunities in currently marketed products, the stock has a Hold rating. BIIB data by YCharts From a pipeline point of view, many analysts consider Alzheimer's development succes… read more...

Biogen: Spinning Around Spinraza

via: SeekingAlpha at 2018-11-13 16:31:42:000

Biogen's ( BIIB ) stock was trading at around $300-$330 within the past month. Due to unimpressive growth opportunities in currently marketed products, the stock has a Hold rating. BIIB data by YCharts From a pipeline point of view, many analysts consider Alzheimer's development succes… read more...

ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-13 05:35:00:000

Read more … read more...

ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q3 2018

via: SeekingAlpha at 2018-11-13 05:35:00:000

Read more … read more...

Amgen's Repatha shows durable treatment effect in long-term study

via: SeekingAlpha at 2018-11-12 16:28:58:000

At the end of the first year of treatment, patients receiving Repatha achieved a 59% reduction in average LDL-C from baseline. In years two, three, four and five, the mean reductions were 56%, 57%, 56% and 56%, respectively. More news on: Amgen Inc., Healthcare stocks news, Read more …. read more...

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018

via: PR Newswire at 2018-11-12 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 12, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the final report of the O pen-Label S tudy of L ong-T ER m Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha (evolocumab) was associated with robust a… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires

via: PR Newswire at 2018-11-12 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 12, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organiza… read more...

Game Plan For The Week - Cramer's Mad Money (11/9/18)

via: SeekingAlpha at 2018-11-12 07:37:24:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday , November 9. The market is reading the decline in oil as an economic weakness. "I read the decline in oil as an issue of supply overwhelming demand, not demand waning. When that happens, it's terrific f… read more...

Investors are flocking to 'quality' stocks. Here's what that means for the market

via: CNBC at 2018-11-12 06:44:00:000

No summary available. read more...

BeyondSpring up 17% on positive plinabulin data

via: SeekingAlpha at 2018-11-09 11:39:40:000

Ultra-thinly traded BeyondSpring ( BYSI +16.6% ) is up on almost a 6x surge in volume, albeit on turnover of only 30K shares, on the heels of encouraging Phase 2 data on plinabulin for the prevention of chemo-induced neutropenia (CIN)(abnormally low levels of white blood cells call… read more...

BeyondSpring up 17% on positive plinabulin data

via: SeekingAlpha at 2018-11-09 11:39:40:000

Ultra-thinly traded BeyondSpring ( BYSI +16.6% ) is up on almost a 6x surge in volume, albeit on turnover of only 30K shares, on the heels of encouraging Phase 2 data on plinabulin for the prevention of chemo-induced neutropenia (CIN)(abnormally low levels of white blood cells call… read more...

BeyondSpring up 17% on positive plinabulin data

via: SeekingAlpha at 2018-11-09 11:39:40:000

Ultra-thinly traded BeyondSpring ( BYSI +16.6% ) is up on almost a 6x surge in volume, albeit on turnover of only 30K shares, on the heels of encouraging Phase 2 data on plinabulin for the prevention of chemo-induced neutropenia (CIN)(abnormally low levels of white blood cells call… read more...

CytomX: A Growth Stock Trading At A Bargain

via: SeekingAlpha at 2018-11-09 09:12:19:000

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger In our continuous search for bar… read more...

CytomX: A Growth Stock Trading At A Bargain

via: SeekingAlpha at 2018-11-09 09:12:19:000

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger In our continuous search for bar… read more...

CytomX: A Growth Stock Trading At A Bargain

via: SeekingAlpha at 2018-11-09 09:12:19:000

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger In our continuous search for bar… read more...

Diversifying By Sector: 20 High-Quality Attractive Dividend Growth Stocks Rated A- Or Better (Part 2B)

via: SeekingAlpha at 2018-11-09 04:20:17:000

Introduction This current series of articles could be summarized as a review of ways to construct and diversify a common stock portfolio. In part 1 found here I discussed various viewpoints on how many stocks a portfolio should hold. In Part 2A found here I presented and discussed Pete… read more...

Diversifying By Sector: 20 High-Quality Attractive Dividend Growth Stocks Rated A- Or Better (Part 2B)

via: SeekingAlpha at 2018-11-09 04:20:17:000

Introduction This current series of articles could be summarized as a review of ways to construct and diversify a common stock portfolio. In part 1 found here I discussed various viewpoints on how many stocks a portfolio should hold. In Part 2A found here I presented and discussed Pete… read more...

Diversifying By Sector: 20 High-Quality Attractive Dividend Growth Stocks Rated A- Or Better (Part 2B)

via: SeekingAlpha at 2018-11-09 04:20:17:000

Introduction This current series of articles could be summarized as a review of ways to construct and diversify a common stock portfolio. In part 1 found here I discussed various viewpoints on how many stocks a portfolio should hold. In Part 2A found here I presented and discussed Pete… read more...

Monthly Review Of DivGro: October 2018

via: SeekingAlpha at 2018-11-09 04:15:11:000

The stock market had a spooky month in October, with volatility as measured by the CBOE VIX increasing by about 75%, from 12 to 21. The DOW 30 dropped 5.1%, the S&P 500 dropped 6.9%, and the NASDAQ dropped 9.2%. When stock prices fall like that, dividend growth investors get a chance to … read more...

Monthly Review Of DivGro: October 2018

via: SeekingAlpha at 2018-11-09 04:15:11:000

The stock market had a spooky month in October, with volatility as measured by the CBOE VIX increasing by about 75%, from 12 to 21. The DOW 30 dropped 5.1%, the S&P 500 dropped 6.9%, and the NASDAQ dropped 9.2%. When stock prices fall like that, dividend growth investors get a chance to … read more...

Monthly Review Of DivGro: October 2018

via: SeekingAlpha at 2018-11-09 04:15:11:000

The stock market had a spooky month in October, with volatility as measured by the CBOE VIX increasing by about 75%, from 12 to 21. The DOW 30 dropped 5.1%, the S&P 500 dropped 6.9%, and the NASDAQ dropped 9.2%. When stock prices fall like that, dividend growth investors get a chance to … read more...

Dividend Increases: October 29-November 2, 2018

via: SeekingAlpha at 2018-11-06 13:11:38:000

One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor … read more...

Dividend Increases: October 29-November 2, 2018

via: SeekingAlpha at 2018-11-06 13:11:38:000

One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor … read more...

Dividend Increases: October 29-November 2, 2018

via: SeekingAlpha at 2018-11-06 13:11:38:000

One way to identify dividend growth stocks for further analysis is to monitor dividend increases. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stocks to monitor … read more...

Why We Pass On Amgen

via: SeekingAlpha at 2018-11-06 11:53:32:000

Amgen's stock is the leading iShares Nasdaq Biotechnology ETF ( IBB ) component. However, we don't think that its stock is going to grow faster than other stocks represented in IBB. While other major biotech companies have suffered stock declines due to weakened sales forecast, Amgen has not… read more...

Why We Pass On Amgen

via: SeekingAlpha at 2018-11-06 11:53:32:000

Amgen's stock is the leading iShares Nasdaq Biotechnology ETF ( IBB ) component. However, we don't think that its stock is going to grow faster than other stocks represented in IBB. While other major biotech companies have suffered stock declines due to weakened sales forecast, Amgen has not… read more...

Why We Pass On Amgen

via: SeekingAlpha at 2018-11-06 11:53:32:000

Amgen's stock is the leading iShares Nasdaq Biotechnology ETF ( IBB ) component. However, we don't think that its stock is going to grow faster than other stocks represented in IBB. While other major biotech companies have suffered stock declines due to weakened sales forecast, Amgen has not… read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

via: PR Newswire at 2018-11-05 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 5, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, evaluating the long-term safety and efficacy of Repatha (evolocumab) in patients w… read more...

Advaxis, Revisited

via: SeekingAlpha at 2018-11-05 14:01:01:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Most of my readers will know A… read more...

Provention Bio up 12% on co-development deal with Amgen

via: SeekingAlpha at 2018-11-05 09:57:59:000

Thinly traded micro cap Provention Bio ( PRVB +12.4% ) is up on modestly higher volume in early trade in response to its agreement to co-develop AMG 714 with Amgen ( AMGN +0.9% ) for the treatment of patients with celiac disease that is unresponsive to a gluten-free diet. Provention ha… read more...

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

via: PR Newswire at 2018-11-05 09:00:00:000

THOUSAND OAKS, Calif. and OLDWICK, N.J. , Nov. 5, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, i… read more...

Nicholas Ward's Dividend Growth Portfolio: October Update

via: SeekingAlpha at 2018-11-05 07:45:31:000

Last month, I posted my quarterly results and said that I would try and do a better job of posting regular portfolio updates for those readers/followers who dont track Seeking Alpha on a daily basis and miss my trade-related stock talks. Well, here we go. October was a crazy month fo… read more...

It's Time To Buy Microsoft - Cramer's Lightning Round (11/2/18)

via: SeekingAlpha at 2018-11-05 06:37:07:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, November 2 . Bullish Calls Microsoft (MSFT): They reported a good quarter and the stock went down due to a selloff in tech. It's time to buy. ResMed (RMD): CEO Mark Farrell is doing a good job… read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

Cramer's lightning round: It's time to buy the stock of Microsoft

via: CNBC at 2018-11-02 18:47:00:000

No summary available. read more...

FDA OKs Coherus Bio's Neulasta biosimilar shares up 7%

via: SeekingAlpha at 2018-11-02 13:45:32:000

The FDA approves Coherus BioSciences' ( CHRS +6.8% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar to Amgen's ( AMGN -2.3% ) Neulasta, the first for the company. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Coherus Bio's Neulasta biosimilar shares up 7%

via: SeekingAlpha at 2018-11-02 13:45:32:000

The FDA approves Coherus BioSciences' ( CHRS +6.8% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar to Amgen's ( AMGN -2.3% ) Neulasta, the first for the company. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Coherus Bio's Neulasta biosimilar shares up 7%

via: SeekingAlpha at 2018-11-02 13:45:32:000

The FDA approves Coherus BioSciences' ( CHRS +6.8% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar to Amgen's ( AMGN -2.3% ) Neulasta, the first for the company. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

RED WAVE, BLUE WAVE: What could happen to markets if Republicans win big or lose big on Tuesday

via: CNBC at 2018-11-02 09:40:00:000

No summary available. read more...

RED WAVE, BLUE WAVE: What could happen to markets if Republicans win big or lose big on Tuesday

via: CNBC at 2018-11-02 09:40:00:000

No summary available. read more...

RED WAVE, BLUE WAVE: What could happen to markets if Republicans win big or lose big on Tuesday

via: CNBC at 2018-11-02 09:40:00:000

No summary available. read more...

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018

via: PR Newswire at 2018-11-01 16:00:00:000

THOUSAND OAKS, Calif. , Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data will be presented at the 60 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego , Dec. 1-4, 2018 . Data across an array of malignancies will … read more...

FDA OKs genetic test to inform on drug metabolism

via: SeekingAlpha at 2018-11-01 09:33:04:000

The FDA approves a consumer-targeted molecular diagnostic test from privately held 23andme , the Personal Genome Service Pharmacogenetic Reports, that detects 33 variants for multiple genes from a saliva sample. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnolog… read more...

Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program

via: PR Newswire at 2018-11-01 09:00:00:000

THOUSAND OAKS, Calif. , Nov. 1, 2018 /PRNewswire/ --The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-ye… read more...

Cancer Research Highlight: Genmab Continues To Storm Into Frontline Myeloma

via: SeekingAlpha at 2018-10-31 15:36:13:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par… read more...

AbbVie down 4% on Humira price cut in Europe

via: SeekingAlpha at 2018-10-31 15:35:35:000

AbbVie ( ABBV -3.9% ) slips on more than 60% higher volume in what would be a reasonable reaction by investors following the FDA nod for Novartis' Humira biosimilar Myrimoz. More news on: AbbVie Inc., Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, Read more … ... read more...

DivGro Pulse: October 2018

via: SeekingAlpha at 2018-10-31 08:00:58:000

DivGro is my portfolio of dividend growth stocks and I write monthly pulse articles that monitor DivGro's health. These articles are strategy-focused and my overall aim is to reduce portfolio risk and to further diversify my holdings. In the third quarter of 2018, I focused specifically on s… read more...

Stocks making the biggest move premarket: GM, ANTM, CLX, EL & more

via: CNBC at 2018-10-31 08:00:00:000

No summary available. read more...

Bulls Pin Hopes On Market Rebound (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-31 07:49:00:000

Today's top stories: Bulls pin hopes on market rebound; Chinese equities tracking gains on Wall Street; and Samsung posts record profit. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking… read more...

Wall Street Breakfast: Rough October Ends On Upbeat Note

via: SeekingAlpha at 2018-10-31 06:59:09:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). European stocks advanced overnight, tracking a rebound across Asia, as U.S. futures extended gains on the last day… read more...

Amgen Inc. (AMGN) CEO Robert Bradway on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-30 23:39:07:000

Amgen Inc. (AMGN) Q3 2018 Results Earnings Conference Call October 30, 2018, 05:00 PM ET Executives Arvind Sood - VP, IR Robert Bradway - Chairman and CEO David Meline - CFO Murdo Gordon - Head, Global Commercial Operations David Reese - EVP, R&D Tony Hooper - EVP, Glob… read more...

Amgen Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-30 16:36:02:000

The following slide deck was published by Amgen Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Amgen Q3 top line up 2%; earnings down 8%; guidance raised

via: SeekingAlpha at 2018-10-30 16:12:22:000

Amgen (NASDAQ: AMGN ) Q3 results ($M): Revenues: 5,904 (+2.3%). More news on: Amgen Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Amgen beats by $0.24, beats on revenue

via: SeekingAlpha at 2018-10-30 16:02:14:000

Amgen (NASDAQ: AMGN ): Q3 Non-GAAP EPS of $3.69 beats by $0.24; GAAP EPS of $2.86 misses by $0.16. Revenue of $5.9B (+2.3% Y/Y) beats by $120M . Shares +1.2% . Press Release More news on: Amgen Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Top st… read more...

Amgen Reports Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-30 16:01:00:000

THOUSAND OAKS, Calif. , Oct. 30, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion . Product sales grew 1 percent gl… read more...

Glaxo's daprodustat on par with Amgen's Aranesp in late-stage study in Japan

via: SeekingAlpha at 2018-10-30 07:51:22:000

Results from a Japan-based Phase 3 clinical trial evaluating GlaxoSmithKline's (NYSE: GSK ) oral daprodustat in dialysis-dependent patients with anemia associated with chronic kidney disease showed it to be non-inferior to Amgen's (NASDAQ: AMGN ) Aranesp (darbepoetin alfa) injection as … read more...

Dow rallies more than 400 points in bounce as brutal October nears a close

via: CNBC at 2018-10-30 05:00:00:000

No summary available. read more...

Notable earnings after Tuesday's close

via: SeekingAlpha at 2018-10-29 17:35:13:000

ACGL , AEGN , AFG , AINV , AMGN , APAM , APC , BAND , BEAT , BGS , BHE , BIDU , BJRI , BXP , CAI , CAKE , CHRW , CLVS , CONE , CRAY , CW , CXO , DDD , DENN , EA , EBAY , EIX , ESIO , EVTC , EXAS , EXR , FB , FEYE , FLT , GNW , H , HABT , HCLP , HLF , … read more...

Most Important Earnings To Watch This Week

via: SeekingAlpha at 2018-10-29 12:13:01:000

We're smack dab in the middle of earnings season right now, and below is a list of the 40 largest companies set to report Q3 numbers this week. For each stock, we include a number of key data points that you won't find in most earnings calendars. Data points like historical earnings and revenu… read more...

Dova: From Unmet Needs To Playing With Giants

via: SeekingAlpha at 2018-10-29 09:00:00:000

Dova Pharmaceuticals ( DOVA ) is a commercial stage biotech company, which has had their first product, avatrombopag or DOPTELET, approved by the FDA in May 2018 for treatment of thrombocytopenia (NYSE: TCP ) in adult patients with chronic liver disease (NYSE: CLD ). They have since launched t… read more...

Equity Investing In This Rate-Hiking Environment

via: SeekingAlpha at 2018-10-29 08:53:37:000

Background "The interest rate is the gravity to stock valuations," Warren Buffett often quoted when responding to how to predict stock prices. While the statement is almost useless for investors to make future returns as no one can really predict the interest rate, it does reflect what happe… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

via: PR Newswire at 2018-10-26 19:54:00:000

THOUSAND OAKS, Calif. , Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function. In line w… read more...

Amgen Announces Webcast Of 2018 Third Quarter Financial Results

via: PR Newswire at 2018-10-26 16:00:00:000

THOUSAND OAKS, Calif. , Oct. 26, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wi… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Amgen cuts price of Repatha 60%

via: SeekingAlpha at 2018-10-24 16:06:46:000

Apparently out of patience with the slow ramp of Repatha (evolocumab), Amgen (NASDAQ: AMGN ) hopes to stoke demand with a healthy 60% discount off list to $5,850 per year. The company says the price cut will improve affordability by lowering co-pays, especially for Medicare beneficiaries. … read more...

Amgen cuts price of Repatha 60%

via: SeekingAlpha at 2018-10-24 16:06:46:000

Apparently out of patience with the slow ramp of Repatha (evolocumab), Amgen (NASDAQ: AMGN ) hopes to stoke demand with a healthy 60% discount off list to $5,850 per year. The company says the price cut will improve affordability by lowering co-pays, especially for Medicare beneficiaries. … read more...

Amgen cuts price of cholesterol drug by almost 60%, echoing rival's move

via: CNBC at 2018-10-24 16:01:00:000

No summary available. read more...

Amgen cuts price of cholesterol drug by almost 60%, echoing rival's move

via: CNBC at 2018-10-24 16:01:00:000

No summary available. read more...

Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price

via: PR Newswire at 2018-10-24 16:00:00:000

THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced that it is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price… read more...

Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price

via: PR Newswire at 2018-10-24 16:00:00:000

THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced that it is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price… read more...

First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate

via: PR Newswire at 2018-10-24 09:00:00:000

THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psori… read more...

First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate

via: PR Newswire at 2018-10-24 09:00:00:000

THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psori… read more...

Amgen Announces 2018 Fourth Quarter Dividend

via: PR Newswire at 2018-10-23 16:00:00:000

THOUSAND OAKS, Calif. , Oct. 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will be paid on Dec. 7, 2018 , to all stockholders of record as of the close of bu… read more...

BeyondSpring's Plinabulin shows positive effect in preventing chemo-induced neutropenia

via: SeekingAlpha at 2018-10-23 10:51:37:000

A Phase 2 clinical trial evaluating BeyondSpring's ( BYSI -4% ) Plinabulin, combined with Amgen's ( AMGN -1.9% ) Neulasta (pegfilgrastim), for the prevention of chemo-induced neutropenia (CIN) low and bone pain demonstrated a treatment effect. More news on: BeyondSpring Inc., Amgen I… read more...

Biotechs set for down gap at open

via: SeekingAlpha at 2018-10-23 09:25:19:000

The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is down 2% premarket on light volume, continuing its 2% slide yesterday. More news on: SPDR Biotech ETF, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Roche Is Taking Amgen's BiTE Concept In Leukemia To Solid Tumors

via: SeekingAlpha at 2018-10-22 15:10:36:000

Amgens ( AMGN ) Blincyto blinatumomab, a bispecific antibody, is proof of concept that T cells can be retargeted against leukemia cells without engineering them ex vivo to express anti-CD19 receptors (i.e., CAR-T cells). Currently, 53 trials of anti-CD19/CD3 blinatumomab are registered… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies

via: PR Newswire at 2018-10-18 09:00:00:000

THOUSAND OAKS, Calif. and OXFORD, England , Oct. 18, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of 50 million ( $66 million ) in Oxford Nanopore, a privately-owned, UK-based company advancing a new … read more...

Stocks making the biggest move premarket: NFLX, IBM, CSX, UAL, TEVA & more

via: CNBC at 2018-10-17 07:57:00:000

No summary available. read more...

Teva down 4% premarket on Express Scripts snub of migraine med Ajovy

via: SeekingAlpha at 2018-10-17 07:28:37:000

Teva Pharmaceutical Industries (NYSE: TEVA ) slips 4% premarket on light volume on the heels of a Bloomberg report that Express Scripts (NASDAQ: ESRX ) has excluded migraine med AJOVY (fremanezumab-vfrm). The FDA approved it a month ago. More news on: Teva Pharmaceutical Indust… read more...

10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

via: SeekingAlpha at 2018-10-16 08:28:14:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 12.36% to 23.08% Gains To October 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for t… read more...

Jerry Maguire Stock Market

via: SeekingAlpha at 2018-10-16 00:52:27:000

The actor Tom Cruise is as enigmatic as the U.S. stock market. He has made many terrific movies over the years and todays stock market reminds us of his classic sports movie, Jerry Maguire . Jerry was a top sports agent for a large agency and then suddenly, out of nowhere, was dumped … read more...

Amgen Launches AMGEVITA(TM) (Biosimilar Adalimumab) In Markets Across Europe

via: PR Newswire at 2018-10-16 00:00:00:000

THOUSAND OAKS, Calif. , Oct. 15, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that AMGEVITA TM , a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018 . AMGEVITAis the first adalimumab biosimilar to be approved by the Europea… read more...

FDA issues new guidance aimed at more efficient drug development

via: SeekingAlpha at 2018-10-15 13:49:33:000

The FDA has issued two guidance documents that it says should help make the drug development process more efficient. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, … read more...

Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends

via: SeekingAlpha at 2018-10-15 00:50:49:000

Simplicity is the ultimate sophistication. There is an almost infinite amount of variables to consider when making investment decisions. However, the smart thing to do is focusing on the variables that can have a stronger impact on your returns and risk in the market. At the end of the day, … read more...

A Company In Decline? The Case For/Against Affimed After Bad News

via: SeekingAlpha at 2018-10-14 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy has become one o… read more...

Retirement: How To Manage Risks And Prepare For The Next Downturn

via: SeekingAlpha at 2018-10-13 09:00:00:000

Let's say you already have a million dollar portfolio, mostly invested in the index funds. The bull market of the last 10 years has helped your portfolio tremendously due to the outperformance of the broad market indexes. It has been difficult for most people and strategies to beat the broad m… read more...

The October Pause That Refreshes

via: SeekingAlpha at 2018-10-11 18:02:50:000

Well, here it is! The much-awaited correction, which everybody has been awaiting to finally invest in U.S. equities. Guess whatit will be like it has almost always been (and definitely many times during this, still the most hated/distrusted stock bull market in my memory). Most inv… read more...

The October Pause That Refreshes

via: SeekingAlpha at 2018-10-11 18:02:50:000

Well, here it is! The much-awaited correction, which everybody has been awaiting to finally invest in U.S. equities. Guess whatit will be like it has almost always been (and definitely many times during this, still the most hated/distrusted stock bull market in my memory). Most inv… read more...

My K.I.S.S. Dividend Growth Portfolio: 3rd Quarter 2018 Update

via: SeekingAlpha at 2018-10-09 11:41:47:000

Ummm, well, I guess dont have much in the way of interesting or insightful introductory thoughts for this portfolio update. My portfolio just keeps chugging along producing more and more dividends. So lets just proceed with the data. First, if you wish to review my previous q… read more...

My K.I.S.S. Dividend Growth Portfolio: 3rd Quarter 2018 Update

via: SeekingAlpha at 2018-10-09 11:41:47:000

Ummm, well, I guess dont have much in the way of interesting or insightful introductory thoughts for this portfolio update. My portfolio just keeps chugging along producing more and more dividends. So lets just proceed with the data. First, if you wish to review my previous q… read more...

Danger Zone: Rise Of The Noise Traders

via: SeekingAlpha at 2018-10-09 11:38:08:000

Noise traders - individuals that distort the market by trading on incomplete or inaccurate information - have been discussed by academics and investors alike for decades. [1] No one could ever deny the existence of noise traders, but proponents of the efficient market hypothesis (EMH) have lo… read more...

Danger Zone: Rise Of The Noise Traders

via: SeekingAlpha at 2018-10-09 11:38:08:000

Noise traders - individuals that distort the market by trading on incomplete or inaccurate information - have been discussed by academics and investors alike for decades. [1] No one could ever deny the existence of noise traders, but proponents of the efficient market hypothesis (EMH) have lo… read more...

Cancer Research Highlight: Affimed Has A Major Setback; Can They Recover?

via: SeekingAlpha at 2018-10-09 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Affimed Therapeutics ( AFMD ) … read more...

Cancer Research Highlight: Affimed Has A Major Setback; Can They Recover?

via: SeekingAlpha at 2018-10-09 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Affimed Therapeutics ( AFMD ) … read more...

Dividend Income Update September 2018

via: SeekingAlpha at 2018-10-09 05:53:35:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Dividend Income Update September 2018

via: SeekingAlpha at 2018-10-09 05:53:35:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Lilly Surges On Pipeline News: Analysis And Trading Thoughts

via: SeekingAlpha at 2018-10-08 14:49:36:000

Introduction Eli Lilly ( LLY ) has been on a roll, powered by some fast-growing young products, some resiliency of its older stalwarts, and a promising pipeline. See p. 12 of LLY's Q2 detailed earnings release for a list of sales and yoy growth rates for these drugs. The reason I have rent… read more...

Quantitative Value Stock Screener Performance - Q1-Q3 2018

via: SeekingAlpha at 2018-10-08 13:52:56:000

Quantitative Value (QV) is a term for quantitative stock investing strategies which select the highest-quality stocks out of a bucket of cheap stocks. Dr. Wes Gray and Tobias Carlisle were the first to design such a strategy, which they introduced in their book Quantitative Value . Whil… read more...

Crispr Therapeutics Is A Momentum Stock - Cramer's Lightning Round (10/5/18)

via: SeekingAlpha at 2018-10-08 06:55:50:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, October 5 . Bearish Calls Camping World (CWH): It trades in-sync with Thor Industries (THO) which hit a 52-week low. This is not the right time to buy. Spectrum Pharmaceuticals (SPPI): Don't go … read more...

Sand In My Shoes - August (Yes, August) Update

via: SeekingAlpha at 2018-10-07 21:42:52:000

As I sit here in a Florida resort with summer coming to a close, I am contemplating what life will be like when my bride and I will be living off of our investments, and more specifically our dividends. It is likely that both of us have many good working years left to increase our nest egg fur… read more...

Cramer's lightning round: Watch out-momentum stocks are out of favor right now

via: CNBC at 2018-10-05 18:49:00:000

No summary available. read more...

Cramer's lightning round: Watch out-momentum stocks are out of favor right now

via: CNBC at 2018-10-05 18:49:00:000

No summary available. read more...

Cramer's lightning round: Watch out-momentum stocks are out of favor right now

via: CNBC at 2018-10-05 18:49:00:000

No summary available. read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

Nicholas Ward's Dividend Growth Portfolio: Third Quarter Update

via: SeekingAlpha at 2018-10-05 09:05:37:000

The most common messages that I get here at Seeking Alpha are those asking about my holdings. Ive come to learn that readers, new and old, like to know what makes up contributors' portfolios. I dont blame them; its nice to know that writers have a bit of skin in the g… read more...

Nicholas Ward's Dividend Growth Portfolio: Third Quarter Update

via: SeekingAlpha at 2018-10-05 09:05:37:000

The most common messages that I get here at Seeking Alpha are those asking about my holdings. Ive come to learn that readers, new and old, like to know what makes up contributors' portfolios. I dont blame them; its nice to know that writers have a bit of skin in the g… read more...

Nicholas Ward's Dividend Growth Portfolio: Third Quarter Update

via: SeekingAlpha at 2018-10-05 09:05:37:000

The most common messages that I get here at Seeking Alpha are those asking about my holdings. Ive come to learn that readers, new and old, like to know what makes up contributors' portfolios. I dont blame them; its nice to know that writers have a bit of skin in the g… read more...

Amarin up 14% amid conference presentation

via: SeekingAlpha at 2018-10-03 14:22:22:000

The company late this morning presented at the Cantor healthcare conference. More news on: Amgen Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Stocks on the move, Read more … read more...

Amarin up 14% amid conference presentation

via: SeekingAlpha at 2018-10-03 14:22:22:000

The company late this morning presented at the Cantor healthcare conference. More news on: Amgen Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Stocks on the move, Read more … read more...

The Rose 96 Stock Portfolio Due Diligence Criteria Exposed Along With Some Value Buys

via: SeekingAlpha at 2018-10-02 14:32:12:000

First and foremost, my investing focus has been to build a portfolio of quality blue chip mostly defensive common stock for increased value creation and rising income for the future. The current investments in this portfolio also include RIC (regulated investment companies), high yield, ETFs a… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

Eli Lilly Looks To Be A Strong Competitor In The Preventative Migraine Market

via: SeekingAlpha at 2018-10-01 22:57:13:000

Recently, Eli Lilly ( LLY ) announced that it had received FDA approval for its migraine prevention drug known as Emgality. This FDA approval puts the company on the map to go after a big market. There are a few competitors, but I believe that there is plenty of market share for all thes… read more...

The R.I.P. Portfolio's Q3 2018 Update

via: SeekingAlpha at 2018-10-01 12:06:38:000

The Retire In Peace portfolio , or R.I.P. portfolio , was first introduced to the Seeking Alpha ("SA") community in December 2015 and I have published quarterly articles that captured the activity and performance of the portfolio since that point in time. The companies that I write about o… read more...

How Libtayo's Approval May Help Cure Regeneron's Remaining Ills

via: SeekingAlpha at 2018-10-01 09:40:46:000

The main problem Regeneron ( REGN ) has experienced immense stock market success in the nearly 7 years since its mega-blockbuster drug for retinal diseases, Eylea, was approved by the FDA. The stock has risen from about $55 in October 2011 to a current $404 as of Friday's close, a 33% CAGR. … read more...

FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma

via: PR Newswire at 2018-10-01 09:00:00:000

THOUSAND OAKS, Calif. , Oct. 1, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS (carfilzomib) to include a on… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-01 08:48:56:000

Neon Therapeutics (NASDAQ: NTGN ) initiated with Buy rating and $20 (134% upside) price target at Ladenburg Thalmann. More news on: Neon Therapeutics, Incyte Corporation, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, , Read more … read more...

Investors Need To PAAY Attention To This Information

via: SeekingAlpha at 2018-09-30 22:05:47:000

Over the past 5+ years, I have been posting my KISS portfolio on Seeking Alpha. During that time, I have used my PAAY system to reinvest my dividends. PAAY stands for Percentage Above Average Yield. My theory behind the system is that when a dividend growth stock is trading at a price which gi… read more...

Can Biotech Stocks Power Ahead?

via: SeekingAlpha at 2018-09-28 20:14:38:000

(Image Source ) Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF ( IBB ) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull m… read more...

Can Biotech Stocks Power Ahead?

via: SeekingAlpha at 2018-09-28 20:14:38:000

(Image Source ) Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF ( IBB ) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull m… read more...

Lilly to be "aggressive" with rollout of migraine med Emgality - Bloomberg

via: SeekingAlpha at 2018-09-28 09:27:00:000

Bloomberg reports that Eli Lilly (NYSE: LLY ) plans to offer prospective patients a free 12-month supply of just-approved migraine med Emgality (galcanezumab-gnlm). More news on: Eli Lilly and Company, Amgen Inc., Healthcare stocks news, Read more … read more...

Stocks making the biggest move premarket: BB, LOW, MTN, TSLA, BA & more

via: CNBC at 2018-09-28 07:58:00:000

No summary available. read more...

Tesla Tops Headlines Again As SEC Sues Musk (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-09-28 07:43:37:000

Today's Top Stories: Tesla tops headlines again as SEC sues Musk; Japan's Nikkei hits 27-day intraday high; and Google CEO meets with Republican lawmakers. Click play to listen in your browser. If you are interested in listening to Wall Street Breakfast to start your day, look f… read more...

Wall Street Breakfast: Tesla Tops The Headlines Again As SEC Sues Musk

via: SeekingAlpha at 2018-09-28 06:47:32:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The SEC is suing Elon Musk, accusing the Tesla (TSLA) CEO of securities fraud and seeking to ban him from serving as … read more...

Eli Lilly says FDA approves new migraine drug

via: SeekingAlpha at 2018-09-28 04:14:15:000

The Food and Drug Administration approved Eli Lilly's (NYSE: LLY ) Emgality injection for the preventive treatment of migraine in adults, one of three in a new class of drugs recently approved for migraines. More news on: Eli Lilly and Company, Amgen Inc., Novartis AG, Healthcare stocks… read more...

Alzheon Proposes Terms For Smaller IPO

via: SeekingAlpha at 2018-09-27 13:44:37:000

Quick Take Alzheon ( ALZH ) intends to raise $35 million from the sale of its common stock in an IPO, per an amended registration statement . The company is developing an orally-delivered formulation of tramiprosate for the treatment of Alzheimers disease. ALZH has a small cap… read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

Coherus Bio's Neulasta biosimilar OK'd in Europe; shares up 6%

via: SeekingAlpha at 2018-09-25 13:59:33:000

The European Commission (EC) approves Coherus BioSciences' ( CHRS +5.9% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar of Amgen's ( AMGN +0.3% ) Neulasta. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Coherus Bio's Neulasta biosimilar OK'd in Europe; shares up 6%

via: SeekingAlpha at 2018-09-25 13:59:33:000

The European Commission (EC) approves Coherus BioSciences' ( CHRS +5.9% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar of Amgen's ( AMGN +0.3% ) Neulasta. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Arvinas IPO: 40% Is Cash, But Research Is At An Early Stage

via: SeekingAlpha at 2018-09-25 10:03:17:000

With Yale University, Pfizer Inc. ( PFE ), Roche Ltd. ( RHHBY ) and Merck ( MRK ) collaborating with Arvinas Holding ( ARVN ) and shares at 2.5 its cash per share, the company seems a name that should retain the attention of investors. Having said that, Arvinas, which conducts research treatme… read more...

Arvinas IPO: 40% Is Cash, But Research Is At An Early Stage

via: SeekingAlpha at 2018-09-25 10:03:17:000

With Yale University, Pfizer Inc. ( PFE ), Roche Ltd. ( RHHBY ) and Merck ( MRK ) collaborating with Arvinas Holding ( ARVN ) and shares at 2.5 its cash per share, the company seems a name that should retain the attention of investors. Having said that, Arvinas, which conducts research treatme… read more...

BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-09-24 21:00:00:000

THOUSAND OAKS, Calif. , Sept. 24, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblas… read more...

BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-09-24 21:00:00:000

THOUSAND OAKS, Calif. , Sept. 24, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblas… read more...

Express Scripts taking credit for Gilead's planned launch of generic HCV meds

via: SeekingAlpha at 2018-09-24 16:02:45:000

Express Scripts ( ESRX -0.2% ) is congratulating the organization it sees in the mirror over Gilead Sciences' plan to launch generic versions of HCV meds Epclusa and Harvoni. More news on: Express Scripts, Inc., Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthca… read more...

S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion

via: PR Newswire at 2018-09-24 10:01:00:000

NEW YORK , Sept.24, 2018 /PRNewswire/ --S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500 stock buybacks , or share repurchases, totaled $190.6 billion for Q2 2018 , displacing the prior quarterly record of… read more...

Is Now A Good Time To Buy Amgen?

via: SeekingAlpha at 2018-09-24 09:55:30:000

Amgen ( AMGN ) is a market leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. The company is facing growing competitive pressure from biosimilars in recent years, but management is doing a sound job of diversifying … read more...

Gritstone Oncology Prepares Final Terms For IPO

via: SeekingAlpha at 2018-09-21 12:36:25:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise $85 million in an IPO of its common stock, according to an amended registration statement . The company is developing a pipeline of cancer treatments that utilize its AI technologies to better target treatment to each patient&#x201… read more...

Gritstone Oncology Prepares Final Terms For IPO

via: SeekingAlpha at 2018-09-21 12:36:25:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise $85 million in an IPO of its common stock, according to an amended registration statement . The company is developing a pipeline of cancer treatments that utilize its AI technologies to better target treatment to each patient&#x201… read more...

Gritstone Oncology Prepares Final Terms For IPO

via: SeekingAlpha at 2018-09-21 12:36:25:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise $85 million in an IPO of its common stock, according to an amended registration statement . The company is developing a pipeline of cancer treatments that utilize its AI technologies to better target treatment to each patient&#x201… read more...

New opinions from EMA advisor CHMP

via: SeekingAlpha at 2018-09-21 10:07:02:000

Opinions released today from the European Medicines Agency's advisory group CHMP. More news on: Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. ADR, Mylan Inc, Healthcare stocks news, Stocks on the move, Read more … read more...

New opinions from EMA advisor CHMP

via: SeekingAlpha at 2018-09-21 10:07:02:000

Opinions released today from the European Medicines Agency's advisory group CHMP. More news on: Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. ADR, Mylan Inc, Healthcare stocks news, Stocks on the move, Read more … read more...

New opinions from EMA advisor CHMP

via: SeekingAlpha at 2018-09-21 10:07:02:000

Opinions released today from the European Medicines Agency's advisory group CHMP. More news on: Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. ADR, Mylan Inc, Healthcare stocks news, Stocks on the move, Read more … read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

Equillium Begins U.S. IPO Effort

via: SeekingAlpha at 2018-09-20 11:15:02:000

Quick Take Equillium ( EQ ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders. EQ is pursuing a Phase 1b/2 trial for its E… read more...

Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA

via: PR Newswire at 2018-09-20 09:00:00:000

THOUSAND OAKS, Calif. and LOS ANGELES , Sept. 20, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA , a newly formed organization focused on advancing a life science innovation hub i… read more...

Almirall's tildrakizumab OK'd in Europe for plaque psoriasis

via: SeekingAlpha at 2018-09-19 12:51:18:000

The European Commission approves Almirall's ( OTC:LBTSF ) ILUMETRI (tildrakizumab), an IL-23 inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis. More news on: Almirall SA, Bristol-Myers Squibb Company, AbbVie Inc., Healthcare stocks news, Read more … read more...

My Quarterly Global Portfolio Update

via: SeekingAlpha at 2018-09-19 10:22:28:000

Background The long-term-focused long-only investment strategy for my global portfolio is no different from the one for my US-centric portfolio , except that it takes taxation into consideration, therefore, leading to the following implications: The portfolio is more biased towards no… read more...

GameStop's Fundamentals Are Declining - Cramer's Lightning Round (9/18/18)

via: SeekingAlpha at 2018-09-19 06:01:00:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, September 18 . Bullish Calls Biogen Inc. (BIIB): Cramer did not like the hype involving its Alzheimer's drug. He prefers Regeneron (REGN) and Amgen (AMGN). Delek US Holdings (DK): Cramer likes … read more...

Cramer's lightning round: With those fundamentals, I can't recommend GameStop here

via: CNBC at 2018-09-18 18:51:00:000

No summary available. read more...

AbbVie used kickbacks to boost Humira sales - CA insurance commissioner

via: SeekingAlpha at 2018-09-18 14:21:30:000

AbbVie ( ABBV -1.7% ) slips on below-average volume in apparent reaction to a lawsuit filed by the California Insurance Commissioner alleging that the company used a "stealthy" network of nurses and kickbacks to doctors to boost prescriptions of top seller Humira. More news on: AbbVie … read more...

World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime

via: PR Newswire at 2018-09-17 16:30:00:000

THOUSAND OAKS, Calif. , Sept. 17, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of Alzhei… read more...

Amgen Inc. at the BofAML Global Health Conference 2018 Presentation

via: SeekingAlpha at 2018-09-14 11:03:18:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen Inc. at the BofAML Global Health Conference 2018 Presentation

via: SeekingAlpha at 2018-09-14 11:03:18:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen Inc. at the BofAML Global Health Conference 2018 Presentation

via: SeekingAlpha at 2018-09-14 11:03:18:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen's (AMGN) Management on BofAML Global Health Conference 2018 - Transcript

via: SeekingAlpha at 2018-09-14 10:57:07:000

Amgen Inc. (AMGN) BofAML Global Health Conference 2018 September 14, 2018 5:00 AM ET Executives David Meline Executive Vice President and Chief Financial Officer Arvind Sood Vice President-Investor Relations Analysts Ying Huang BofA Merrill Lynch … read more...

Amgen's (AMGN) Management on BofAML Global Health Conference 2018 - Transcript

via: SeekingAlpha at 2018-09-14 10:57:07:000

Amgen Inc. (AMGN) BofAML Global Health Conference 2018 September 14, 2018 5:00 AM ET Executives David Meline Executive Vice President and Chief Financial Officer Arvind Sood Vice President-Investor Relations Analysts Ying Huang BofA Merrill Lynch … read more...

Amgen's (AMGN) Management on BofAML Global Health Conference 2018 - Transcript

via: SeekingAlpha at 2018-09-14 10:57:07:000

Amgen Inc. (AMGN) BofAML Global Health Conference 2018 September 14, 2018 5:00 AM ET Executives David Meline Executive Vice President and Chief Financial Officer Arvind Sood Vice President-Investor Relations Analysts Ying Huang BofA Merrill Lynch … read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

Amgen's (AMGN) CEO Bob Bradway on Morgan Stanley Healthcare Conference - Transcript

via: SeekingAlpha at 2018-09-12 14:20:50:000

Amgen Inc. (AMGN) Morgan Stanley Healthcare Conference September 12, 2018 9:20 AM ET Executives Bob Bradway Chief Executive Officer Analysts Matthew Harrison Morgan Stanley Presentation Matthew Harrison So great. So thanks for joining us for the next… read more...

Top Dividend Growth Stocks By Sector

via: SeekingAlpha at 2018-09-12 08:16:39:000

Last Saturday, I published the September edition of my 10 Dividend Growth Stocks series. The top-ranked stock this month is Comcast ( CMCSA ), one of five Consumer Discretionary sector stocks in the 10 top-ranked stocks. I rank a selection of the CCC stocks every month and present 10 s… read more...

Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

via: PR Newswire at 2018-09-11 16:00:00:000

THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London . David W. Meline , executive vice president and chief financial officer at… read more...

Amgen Looks To Enter Multiple Myeloma Space: Can It Compete?

via: SeekingAlpha at 2018-09-10 21:47:14:000

Recently, Amgen ( AMGN ) announced positive preliminary results from its study treating patients with relapsed/refractory multiple myeloma. Early indications are highly positive, and I believe that this company could end up being a strong contender in this space. Early data shows that a majo… read more...

AstraZeneca Looks To Its Asthma Drug For Blockbuster Potential

via: SeekingAlpha at 2018-09-10 21:13:22:000

Recently, AstraZeneca (AZN) and its partner Amgen (AMGN) announced that they had received breakthrough therapy designation for their drug tezepelumab. This drug is being developed to treat patients with severe asthma. It is possible that this drug may provide further benefit to a broad par… read more...

Amgen's Aimovig Launch Looks Strong; Monitor Biosimilar Developments

via: SeekingAlpha at 2018-09-10 17:14:06:000

Initial Aimovig Datapoints Suggest a Strong Launch Aimovig is the first of a new class of drugs that block the calcitonin gene-related peptide, also known as anti-CGRPs. Amgen ( AMGN ) believes there is a potential US market of 10 million patients for Aimovig for use in preventing migraines…. read more...

Your Daily Scoop: Compugen's Trial Begins, Tezepelumab Designated, Sarepta's Alternatives

via: SeekingAlpha at 2018-09-10 11:32:22:000

Stocks in the News: CEGN, AMGN Compugen's first patient dosed with COM701 in Phase 1 clinical trial Discussion : First patient is dosed in Phase 1 clinical trial of Compugen's ( CGEN )COM701 indicated as a cancer immunotherapy antibody targeting PVRIG. The safety and tolerability of t… read more...

My Quarterly Non-Taxable Portfolio Update

via: SeekingAlpha at 2018-09-10 10:24:13:000

Background My loyal readers should be familiar with the following factors (weights in descending order) that I use to determine the fundamental quality of each stock: Management's capital allocation skills (check out the Importance of ROIC ). Growth ( this matters only in cases of… read more...

Income Investors: For Every 2 Ts, Buy 1 HD

via: SeekingAlpha at 2018-09-10 09:00:00:000

Today, we are going to provide a slightly different perspective for Income Investors. The term "Income Investors" does not necessarily mean retirees or near-retirees. Even younger investors could be income-oriented investors even though they may not need the income today or even for a decade o… read more...

Amgen To Present At The Morgan Stanley Global Healthcare Conference

via: PR Newswire at 2018-09-07 16:00:00:000

THOUSAND OAKS, Calif. , Sept. 7, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres… read more...

Amgen To Present At The Morgan Stanley Global Healthcare Conference

via: PR Newswire at 2018-09-07 16:00:00:000

THOUSAND OAKS, Calif. , Sept. 7, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres… read more...

Amgen To Present At The Morgan Stanley Global Healthcare Conference

via: PR Newswire at 2018-09-07 16:00:00:000

THOUSAND OAKS, Calif. , Sept. 7, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres… read more...

Arrowhead's Data Proves That It Can Be A Big Contender In The Hepatitis B Space

via: SeekingAlpha at 2018-09-07 10:06:14:000

Recently, Arrowhead Pharmaceuticals ( ARWR ) announced initial results for its Hepatitis B clinical candidate ARO-HBV. These results were highly positive, and the reason why the stock closed the day higher on Thursday by 37.52% to $19.39 per share. These initial positive results for its ARO-… read more...

Arrowhead's Data Proves That It Can Be A Big Contender In The Hepatitis B Space

via: SeekingAlpha at 2018-09-07 10:06:14:000

Recently, Arrowhead Pharmaceuticals ( ARWR ) announced initial results for its Hepatitis B clinical candidate ARO-HBV. These results were highly positive, and the reason why the stock closed the day higher on Thursday by 37.52% to $19.39 per share. These initial positive results for its ARO-… read more...

Arrowhead's Data Proves That It Can Be A Big Contender In The Hepatitis B Space

via: SeekingAlpha at 2018-09-07 10:06:14:000

Recently, Arrowhead Pharmaceuticals ( ARWR ) announced initial results for its Hepatitis B clinical candidate ARO-HBV. These results were highly positive, and the reason why the stock closed the day higher on Thursday by 37.52% to $19.39 per share. These initial positive results for its ARO-… read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Buy United Parcel Service - Cramer's Lightning Round (9/6/18)

via: SeekingAlpha at 2018-09-07 07:17:36:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better … read more...

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

via: PR Newswire at 2018-09-07 02:00:00:000

THOUSAND OAKS, Calif. , Sept. 6, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic … read more...

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

via: PR Newswire at 2018-09-07 02:00:00:000

THOUSAND OAKS, Calif. , Sept. 6, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic … read more...

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

via: PR Newswire at 2018-09-07 02:00:00:000

THOUSAND OAKS, Calif. , Sept. 6, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic … read more...

Principia Biopharma Readies $75 Million IPO Plans

via: SeekingAlpha at 2018-09-06 10:42:07:000

Quick Take Principia Biopharma ( PRNB ) intends to raise $75.0 million from the sale of its common stock, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for pemphigus, purpura and other diseases. PRNB is a mid-stage biopharma… read more...

Amgen And LabCentral Open Nomination Process For Lab Residency

via: PR Newswire at 2018-09-05 09:00:00:000

CAMBRIDGE, Mass. , Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an … read more...

Your Cancer Highlight: Advaxis Resurrects A 'Dead' Bone Cancer Program

via: SeekingAlpha at 2018-09-04 16:40:24:000

One of the core criticisms that shareholders of Advaxis ( ADXS ) have had with management of the company has been an inability to capitalize on seemingly promising clinical data, as programs using their attenuated listeria-based immunotherapy languish on the vine, unable (apparently) to gain t… read more...

7 Quality Dividend Growth Stocks I Don't (Yet) Own

via: SeekingAlpha at 2018-09-01 13:47:41:000

Recently, I published the August edition of my monthly 10 Dividend Growth Stock series. For the first time since starting the series in 2014, I own each and every stock in the top 10! While it is satisfying to own the top 10 ranked stocks, not seeing a single new stock that I can research … read more...

7 Quality Dividend Growth Stocks I Don't (Yet) Own

via: SeekingAlpha at 2018-09-01 13:47:41:000

Recently, I published the August edition of my monthly 10 Dividend Growth Stock series. For the first time since starting the series in 2014, I own each and every stock in the top 10! While it is satisfying to own the top 10 ranked stocks, not seeing a single new stock that I can research … read more...

7 Quality Dividend Growth Stocks I Don't (Yet) Own

via: SeekingAlpha at 2018-09-01 13:47:41:000

Recently, I published the August edition of my monthly 10 Dividend Growth Stock series. For the first time since starting the series in 2014, I own each and every stock in the top 10! While it is satisfying to own the top 10 ranked stocks, not seeing a single new stock that I can research … read more...

Your Daily Pharma Scoop: Karyopharm Buoyed, MediNova Succeeds, Ardelyx's Publication

via: SeekingAlpha at 2018-08-31 12:18:51:000

Stocks in the News Karyopharm up 4% ahead of presentation of selinexor data Discussion Karyopharm Therapeutics ( KPTI ) reported that they plan to present, at the Society of Hematologic Oncology ((SOHO)) Annual Meeting in Houston, data from their Phase 2b STORM study evaluating sel… read more...

S&P 500 Upside Breakout - Don't Lose Your Core Stock Positions - Yet

via: SeekingAlpha at 2018-08-31 09:20:41:000

A lot of traders and investors hear the term "Breakout" and wonder what it means. Intuitively, we know it means that the market has broken through some type of upside resistance. To use an analogy, imagine a building with three floors, where the market is on the first floor, attempting to brea… read more...

Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin inhibitors - Endpoints News

via: SeekingAlpha at 2018-08-30 12:36:18:000

Endpoints News' John Carroll reports that Pfizer's failure with domagrozumab in Duchenne muscular dystrophy (DMD) is another black eye for myostatin inhibitors for muscle wasting disorders. More news on: Novartis AG, Amgen Inc., Atara Biotherapeutics, Healthcare stocks news, Read mor… read more...

By The Numbers: Is Biogen A Buy?

via: SeekingAlpha at 2018-08-30 10:00:58:000

Biogen ( BIIB ) is one of the top players in the biotech industry, and the company benefits from a strong position in treatments for neurological and neurodegenerative diseases, such as multiple sclerosis (NYSE: MS ) and neuroimmunology, Alzheimers disease and dementia, movement disord… read more...

Your Cancer Highlight: Just How Far Can Karyopharm Go?

via: SeekingAlpha at 2018-08-30 08:00:00:000

As discussed last week, the treatment space of multiple myeloma is brimming with competition, which is only stiffening as key players enter the arena. One of those key players is Karyopharm (KPTI), which is developing an intriguing targeted therapy that blocks a process called "nuclear expor… read more...

European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

via: PR Newswire at 2018-08-29 09:00:00:000

THOUSAND OAKS, Calif. , Aug. 29, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Phil… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone

via: PR Newswire at 2018-08-27 09:00:00:000

THOUSAND OAKS, Calif. , Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS (carfilzomib) to include a once-… read more...

Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone

via: PR Newswire at 2018-08-27 09:00:00:000

THOUSAND OAKS, Calif. , Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS (carfilzomib) to include a once-… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

Gritstone Oncology Files For $80 Million U.S. IPO

via: SeekingAlpha at 2018-08-24 11:45:07:000

Quick Take Gritstone Oncology ( GRTS ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1 registration statement . The firm provides personalized immunotherapy treatments for cancer patients. GRTS has an interesting approach but hasnt entered t… read more...

Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

via: SeekingAlpha at 2018-08-24 08:00:00:000

For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su… read more...

Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

via: SeekingAlpha at 2018-08-24 08:00:00:000

For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su… read more...

Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma

via: SeekingAlpha at 2018-08-24 08:00:00:000

For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-08-24 07:11:19:000

Noteworthy events for the week of August 26 - September 1 for healthcare investors. More news on: Amgen Inc., Pfizer Inc., Bausch Health Companies Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-08-24 07:11:19:000

Noteworthy events for the week of August 26 - September 1 for healthcare investors. More news on: Amgen Inc., Pfizer Inc., Bausch Health Companies Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-08-24 07:11:19:000

Noteworthy events for the week of August 26 - September 1 for healthcare investors. More news on: Amgen Inc., Pfizer Inc., Bausch Health Companies Inc., Healthcare stocks news, , Read more … read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Own A Bond Instead Of Ford - Cramer's Lightning Round (8/22/18)

via: SeekingAlpha at 2018-08-23 06:53:52:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, August 22. Bullish Calls XPO Logistics (XPO): CEO Brad Jacobs is doing a great job and the chart for the stock looks good. Dropbox (DBX): The sellers have got it wrong and the company has a gr… read more...

Cramer's lightning round: Pick this stock for a biotech play

via: CNBC at 2018-08-22 18:44:00:000

No summary available. read more...

Principia Biopharma Begins U.S. IPO Effort

via: SeekingAlpha at 2018-08-22 11:49:35:000

Quick Take Principia Biopharma ( PRNB ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The clinical-stage biopharmaceutical firm researches and develops pharmaceutical treatments for inflammatory and autoimmune diseases. … read more...

Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018

via: PR Newswire at 2018-08-21 08:00:00:000

THOUSAND OAKS, Calif. , Aug. 21, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced the upcoming presentation of new Repatha (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients with metabolic syndrome and established ca… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

via: SeekingAlpha at 2018-08-09 12:08:01:000

Introduction to Part 2 Part 1 of this 2-part series on Roche ( RHHBY ), the world's largest biotech company, delves into some of the details of its strategy to overcome the ongoing, rolling EU/US patent expirations of its Big 3 oncology products of MabThera/Rituxan, Herceptin and Avastin, … read more...

Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

via: SeekingAlpha at 2018-08-09 12:08:01:000

Introduction to Part 2 Part 1 of this 2-part series on Roche ( RHHBY ), the world's largest biotech company, delves into some of the details of its strategy to overcome the ongoing, rolling EU/US patent expirations of its Big 3 oncology products of MabThera/Rituxan, Herceptin and Avastin, … read more...

Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

via: SeekingAlpha at 2018-08-09 12:08:01:000

Introduction to Part 2 Part 1 of this 2-part series on Roche ( RHHBY ), the world's largest biotech company, delves into some of the details of its strategy to overcome the ongoing, rolling EU/US patent expirations of its Big 3 oncology products of MabThera/Rituxan, Herceptin and Avastin, … read more...

BeiGene launches late-stage study of tislelizumab in first-line lung cancer

via: SeekingAlpha at 2018-08-09 07:29:26:000

BeiGene (NASDAQ: BGNE ) initiates a Phase 3 clinical trial evaluating PD-1 inhibitor tislelizumab, combined with chemo, for the first-line treatment of Chinese patients with advanced squamous non-small cell lung cancer (NSCLC). More news on: BeiGene, Merck & Co Inc., Bristol-Myers Sq… read more...

BeiGene launches late-stage study of tislelizumab in first-line lung cancer

via: SeekingAlpha at 2018-08-09 07:29:26:000

BeiGene (NASDAQ: BGNE ) initiates a Phase 3 clinical trial evaluating PD-1 inhibitor tislelizumab, combined with chemo, for the first-line treatment of Chinese patients with advanced squamous non-small cell lung cancer (NSCLC). More news on: BeiGene, Merck & Co Inc., Bristol-Myers Sq… read more...

BeiGene launches late-stage study of tislelizumab in first-line lung cancer

via: SeekingAlpha at 2018-08-09 07:29:26:000

BeiGene (NASDAQ: BGNE ) initiates a Phase 3 clinical trial evaluating PD-1 inhibitor tislelizumab, combined with chemo, for the first-line treatment of Chinese patients with advanced squamous non-small cell lung cancer (NSCLC). More news on: BeiGene, Merck & Co Inc., Bristol-Myers Sq… read more...

AbbVie Is Looking For New Growth Before Generic Competitors Roll In

via: SeekingAlpha at 2018-08-07 21:27:58:000

AbbVie (ABBV) will be in a huge bind in the coming months and years. That's because its top-selling product, Humira, will have generic competition rolling out. That would cause a huge loss in sales, thus, it is scrambling in hopes of potentially acquiring another pharmaceutical company to ge… read more...

Trump administration opens up more drugs covered by Medicare to price negotiations

via: CNBC at 2018-08-07 18:22:00:000

No summary available. read more...

Biopharma 2018: Growth At A Reasonable Cost (GARC)

via: SeekingAlpha at 2018-08-07 12:00:53:000

I maintain that the prospects for the biopharmaceutical industry are extremely favorable, driven by new drug discovery in oncology, hematology and inflammatory diseases. However, the stock valuations do not seem to reflect the prospects, with the above listed GARC (Growth At a Reasonable Cost)… read more...

There's a big market shift coming and these stocks, including Disney, will benefit most

via: CNBC at 2018-08-07 10:41:00:000

No summary available. read more...

Biogen Hits A Potential Home Run

via: SeekingAlpha at 2018-08-07 10:09:33:000

By Alexander J. Poulos We closely follow the progress of the clinical pipeline of companies in the pharma/biotech sector. Unlike other less product-driven industries, the pharma/biotech sector can experience wide swings in operating performance as a result of the lapsing of patent protection… read more...

Biotech Analysis Central Pharma News: Roche's EMA Advance, Pfizer's New Strategy, Arrowhead's First Amgen Milestone Payment

via: SeekingAlpha at 2018-08-06 17:58:12:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Roche Gets PRIME Designation From European Medicines Agency News: Recently, Roche ( OTCQX:RHHBY ) announced that it had obtained PRIME designation … read more...

The Rose 93 Stock July Portfolio Update: Delightful Spicy Dividends Up 60.2% From 2017

via: SeekingAlpha at 2018-08-06 06:23:43:000

I received 60.2% more income in this past July than I did in 2017. It is up hugely secondary to adding Regulated Investment Companies (RICs) and some preferred income with high yield from numerous sectors. They are spicy yummy income providers. Dividends/distributions or income for the portf… read more...

Nicholas Ward's Dividend Growth Portfolio

via: SeekingAlpha at 2018-08-03 18:15:47:000

Every few months, followers new and old ask me about my actual portfolio. Because Ive spread my holdings out across multiple brokerages, its a lot of spread sheeting work to combine all of the data and typically I shy away from these pieces because frankly, I have better things… read more...

Nicholas Ward's Dividend Growth Portfolio

via: SeekingAlpha at 2018-08-03 18:15:47:000

Every few months, followers new and old ask me about my actual portfolio. Because Ive spread my holdings out across multiple brokerages, its a lot of spread sheeting work to combine all of the data and typically I shy away from these pieces because frankly, I have better things… read more...

Nicholas Ward's Dividend Growth Portfolio

via: SeekingAlpha at 2018-08-03 18:15:47:000

Every few months, followers new and old ask me about my actual portfolio. Because Ive spread my holdings out across multiple brokerages, its a lot of spread sheeting work to combine all of the data and typically I shy away from these pieces because frankly, I have better things… read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

Regeneron: How This Bull Can Continue To Gore The Bears

via: SeekingAlpha at 2018-08-03 13:04:40:000

Introduction Regeneron ( REGN ) pleased the bulls Thursday, reporting Q2 results and holding a conference call before the market opened. The stock traded up from the start and closed at a multi-month high, closing around $397. Revenues were up only 9% yoy, but since all the Sanofi ( SNY … read more...

3 Things In Biotech, August 3: Bristol Assaults Melanoma In Europe Again

via: SeekingAlpha at 2018-08-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Bristol-Myers marches on in European melanoma care Company: Bristol-Myers Squibb ( BMY ) Therapy: Nivolumab Di… read more...

3 Things In Biotech, August 3: Bristol Assaults Melanoma In Europe Again

via: SeekingAlpha at 2018-08-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Bristol-Myers marches on in European melanoma care Company: Bristol-Myers Squibb ( BMY ) Therapy: Nivolumab Di… read more...

3 Things In Biotech, August 3: Bristol Assaults Melanoma In Europe Again

via: SeekingAlpha at 2018-08-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Bristol-Myers marches on in European melanoma care Company: Bristol-Myers Squibb ( BMY ) Therapy: Nivolumab Di… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Amgen declares $1.32 dividend

via: SeekingAlpha at 2018-07-31 16:45:44:000

Amgen (NASDAQ: AMGN ) declares $1.32/share quarterly dividend , in line with previous. More news on: Amgen Inc., Dividend News, Read more … read more...

Amgen declares $1.32 dividend

via: SeekingAlpha at 2018-07-31 16:45:44:000

Amgen (NASDAQ: AMGN ) declares $1.32/share quarterly dividend , in line with previous. More news on: Amgen Inc., Dividend News, Read more … read more...

Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

via: PR Newswire at 2018-07-31 16:15:00:000

THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will us… read more...

Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

via: PR Newswire at 2018-07-31 16:15:00:000

THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will us… read more...

Amgen Announces 2018 Third Quarter Dividend

via: PR Newswire at 2018-07-31 16:00:00:000

THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018 , to all stockholders of record as of the close of bu… read more...

Amgen Announces 2018 Third Quarter Dividend

via: PR Newswire at 2018-07-31 16:00:00:000

THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018 , to all stockholders of record as of the close of bu… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

Arrowhead Pharmaceuticals - Finally, Another Buying Opportunity

via: SeekingAlpha at 2018-07-31 09:58:36:000

Arrowhead Pharmaceuticals ( ARWR ) has had a nice downturn in its stock price recently based on no specific news concerning Arrowhead itself. This downturn in the stock is most likely the result of speculation concerning its relation to Amgen Inc. ( AMGN ) along with understandable profit taki… read more...

Arrowhead Pharmaceuticals - Finally, Another Buying Opportunity

via: SeekingAlpha at 2018-07-31 09:58:36:000

Arrowhead Pharmaceuticals ( ARWR ) has had a nice downturn in its stock price recently based on no specific news concerning Arrowhead itself. This downturn in the stock is most likely the result of speculation concerning its relation to Amgen Inc. ( AMGN ) along with understandable profit taki… read more...

AbbVie: Undervalued And Strong Growth On The Horizon

via: SeekingAlpha at 2018-07-31 09:42:38:000

Pharmaceutical Overview AbbVie Inc. first gained notoriety in 2013, after it was formed during a split of Abbot Laboratories. This was because ( ABBV ) retained the rights to Humira and continued to develop and market the drug. As a treatment for rheumatoid arthritis, crohn's disease, pso… read more...

AbbVie: Undervalued And Strong Growth On The Horizon

via: SeekingAlpha at 2018-07-31 09:42:38:000

Pharmaceutical Overview AbbVie Inc. first gained notoriety in 2013, after it was formed during a split of Abbot Laboratories. This was because ( ABBV ) retained the rights to Humira and continued to develop and market the drug. As a treatment for rheumatoid arthritis, crohn's disease, pso… read more...

AbbVie Offers GARP As Consensus Forecast For Humira Is Too Pessimistic

via: SeekingAlpha at 2018-07-31 09:27:59:000

AbbVie ( ABBV ) investors that fear biosimilars sold the beat-and-raise 2nd quarter earnings report on Friday while Mylan ( MYL ) simultaneously reported positive CHMP opinion for Humira biosimilar, Hulio. Humira will remain the world's top-selling drug in 2018 according to EvaluatePharma …. read more...

AbbVie Offers GARP As Consensus Forecast For Humira Is Too Pessimistic

via: SeekingAlpha at 2018-07-31 09:27:59:000

AbbVie ( ABBV ) investors that fear biosimilars sold the beat-and-raise 2nd quarter earnings report on Friday while Mylan ( MYL ) simultaneously reported positive CHMP opinion for Humira biosimilar, Hulio. Humira will remain the world's top-selling drug in 2018 according to EvaluatePharma …. read more...

3 Things In Biotech, July 31: Progenics Bucks The Doubters

via: SeekingAlpha at 2018-07-31 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac… read more...

3 Things In Biotech, July 31: Progenics Bucks The Doubters

via: SeekingAlpha at 2018-07-31 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac… read more...

Your Daily Pharma Scoop: ADMA Closer To PDUFA, Roche Proceeds, AstraZeneca Flunks

via: SeekingAlpha at 2018-07-30 00:21:18:000

Stocks in News: ADMA, RHHBY FDA accepts ADMA Bio's Bivigam application amendment, action date October 25; shares up 18% Discussion : ADMA Biologics ( ADMA ) announced that its request for amendment to BLA to relaunch BIVIGAM (intravenous immune globulin [human], 10%). PDUFA is on Octo… read more...

3 Things In Biotech, July 29: When Europe Determines Your Fate

via: SeekingAlpha at 2018-07-29 03:31:27:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Amgen gets a rebuff from the EMA Company: Amgen ( AMGN ) Therapy: Blinatumomab Disease:… read more...

Venture Capital Deals Of The Week: WeWork China Gets $500M

via: SeekingAlpha at 2018-07-28 10:20:21:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. WeWork China: SoftBank ([[SFTBF]], [[SFTBY]]) and SoftBank Vision Fund participated in a $500M Series B … read more...

Goldman Sachs sets Street-high PT on Amgen

via: SeekingAlpha at 2018-07-27 07:42:53:000

Amgen (NASDAQ: AMGN ) lands a price target boost from Goldman Sachs after yesterday's earnings smasher and guidance raise. More news on: Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Stocks making the biggest moves premarket: TWTR, MRK, CL, AMZN, SBUX & more

via: CNBC at 2018-07-27 07:42:00:000

No summary available. read more...

Economists Foresee Bumper GDP (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-27 07:34:33:000

Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Today's top … read more...

Wall Street Breakfast: Economists Foresee Bumper GDP

via: SeekingAlpha at 2018-07-27 06:57:36:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The headliner of this action-packed week could come from the latest GDP reading, the official scorecard of the U.S…. read more...

Amgen (AMGN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-27 01:39:16:000

Amgen, Inc. (AMGN) Q2 2018 Earnings Call July 26, 2018 5:00 pm ET Executives Arvind K. Sood - Amgen, Inc. Robert A. Bradway - Amgen, Inc. David W. Meline - Amgen, Inc. Anthony C. Hooper - Amgen, Inc. Sean E. Harper - Amgen, Inc. David M. Reese - Amgen, Inc. Analysts Y… read more...

Amgen Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 21:13:40:000

The following slide deck was published by Amgen Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Amgen Q2 top line up 4%; earnings up 7%; cash flow down 10%

via: SeekingAlpha at 2018-07-26 16:22:32:000

Amgen (NASDAQ: AMGN ) Q2 results ($M): Revenues: 6,059 (+4.3%). More news on: Amgen Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Amgen beats by $0.29, beats on revenue

via: SeekingAlpha at 2018-07-26 16:02:29:000

Amgen (NASDAQ: AMGN ): Q2 EPS of $3.83 beats by $0.29 . More news on: Amgen Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Amgen Announces Succession Plans For Two Executive Officers

via: PR Newswire at 2018-07-26 16:02:00:000

THOUSAND OAKS, Calif. , July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today. After more than 21 years of leadership in the bioph… read more...

Amgen Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 16:01:00:000

THOUSAND OAKS, Calif. , July 26, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion . Product sales grew 2 percen… read more...

Amgen facing hurdles from insurers for migraine med Aimovig

via: SeekingAlpha at 2018-07-26 11:26:06:000

Reuters reports that Amgen's ( AMGN +1.1% ) efforts to establish migraine prevention med Aimovig (erenumab-aooe) in the U.S. before competition arrives in September are being stymied by insurers. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Biogen slump pressures other biotechs

via: SeekingAlpha at 2018-07-26 10:32:00:000

Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2018-07-25 17:35:24:000

AFL , AJG , AMGN , AMZN , ATR , AUY , BCOV , BJRI , BOFI , BOOM , BYD , BZH , CINF , CLD , CMG , COLM , CUBE , CVA , CXP , CY , CYH , DECK , DFS , DLR , EA , EGHT , EIX , ELLI , EMN , ENVA , EW , EXPE , FBHS , FHB , FICO , FII , FIX , FLEX , FSLR , FT… read more...

GlaxoSmithKline strikes $300 million deal with 23andMe for genetics-driven drug research

via: CNBC at 2018-07-25 06:23:00:000

No summary available. read more...

BeiGene launches late-stage study of tislelizumab in first-line lung cancer

via: SeekingAlpha at 2018-07-24 17:00:30:000

The first patient has been dosed in a Phase 3 clinical trial evaluating BeiGene's (NASDAQ: BGNE ) PD-1 inhibitor tislelizumab, combined with chemo, for the treatment of Chinese patients with advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) in a first-line setting. More… read more...

Amgen Announces Webcast of 2018 Second Quarter Financial Results

via: PR Newswire at 2018-07-24 16:00:00:000

THOUSAND OAKS, Calif. , July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with … read more...

4 Members Of The $800+ Billion Market Cap Club

via: SeekingAlpha at 2018-07-24 05:37:20:000

Below is an updated look at the 35 largest S&P 500 companies. It's worth noting that recent gains have put four companies into the $800+ billion market cap club . Apple (AAPL) is still on top with a market cap of $933 billion, followed by Amazon (AMZN) at $873 billion, Alphabet (GOOGL) at… read more...

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

via: PR Newswire at 2018-07-19 16:00:00:000

THOUSAND OAKS, Calif. and LOS ANGELES , July 19, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, … read more...

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

via: PR Newswire at 2018-07-19 16:00:00:000

THOUSAND OAKS, Calif. and LOS ANGELES , July 19, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, … read more...

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

via: PR Newswire at 2018-07-19 16:00:00:000

THOUSAND OAKS, Calif. and LOS ANGELES , July 19, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, … read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

FDA committed to easing approval path for biosimilars

via: SeekingAlpha at 2018-07-18 15:08:45:000

In remarks prepared for a presentation to the Brookings Institution, FDA Commissioner Scott Gottlieb, M.D. says the agency is committed to doing its part to reduce healthcare costs, especially as its relates to biosimilars. So far, the market impact of the 11 biosimilars approved in the U… read more...

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP(TM) And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

via: PR Newswire at 2018-07-18 09:00:00:000

THOUSAND OAKS, Calif. , July 18, 2018 /PRNewswire/ -- Amgen(NASDAQ:AMGN) today announced the launch of Myeloma MVP TM , a national campaign to help those affected by multiple myeloma create their M ost V aluable P lan, an individualized approach for managing their disease. Mult… read more...

Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

via: SeekingAlpha at 2018-07-17 14:16:24:000

Gilead ( GILD ) has annual revenues in the HIV class of drugs of over $14.2 billion, and only has one phase 3 drug in clinical trials to protect its dominance in this category. GILDs $14 billion annual income stream could be in jeopardy, because they are literally one drug approval awa… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA

via: SeekingAlpha at 2018-07-16 03:24:32:000

Stocks in News: ADXS, ATOS FDA lifts clinical hold on Advaxis study of axalimogene filolisbac; shares up 61% premarket Discussion : Advaxis ( ADXS ) announced lifting of hold on its Phase clinical trial of axalimogene filolisbac, in combination with AstraZeneca's Imfinzi (durva… read more...

Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis

via: SeekingAlpha at 2018-07-16 03:21:40:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene Amends Protocol For Phase 2 Multiple Myeloma Study News: Recently, Celgene ( CELG ) announced that it had amended the protocol for a phase … read more...

3 Things In Biotech, July 14: Spiking Some Good News

via: SeekingAlpha at 2018-07-14 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Takeda sticks the landing in post-transplant myeloma Company: Takeda ( TKPYY ) Therapy: Ixazomib Disease: Mult… read more...

3 Things In Biotech, July 14: Spiking Some Good News

via: SeekingAlpha at 2018-07-14 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Takeda sticks the landing in post-transplant myeloma Company: Takeda ( TKPYY ) Therapy: Ixazomib Disease: Mult… read more...

Amgen resubmits U.S. marketing application for osteoporosis med Evenity

via: SeekingAlpha at 2018-07-13 07:09:50:000

Amgen (NASDAQ: AMGN ) has refiled its U.S. marketing application seeking approval for EVENITY (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. More news on: Amgen Inc., UCB S.A., UCB S.A. ADR, Healthcare stocks news, Read more … read more...

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA

via: PR Newswire at 2018-07-13 01:00:00:000

THOUSAND OAKS, Calif. and BRUSSELS , July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY* (romosozumab), an inves… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Big Pharma in the red after Pfizer backs away from price hikes

via: SeekingAlpha at 2018-07-11 09:54:56:000

Members of Big Pharma are down in early trade after Pfizer ( PFE -0.6% ) rolled back its planned price increases after direct intervention from President Trump. Investors apparently perceive diminished prospects for large price increases in the future for drug makers. More news on: Pfize… read more...

Your first trade for Wednesday, July 11

via: CNBC at 2018-07-11 09:17:00:000

No summary available. read more...

Pricing transparency law in California having effect, drug makers nix planned increases

via: SeekingAlpha at 2018-07-10 16:12:53:000

Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency. The law, requiring drug makers to give advance notice of significant price increases, is designed … read more...

Replimune Readies $100 Million U.S. IPO

via: SeekingAlpha at 2018-07-10 15:35:28:000

Quick Take Replimune Group ( REPL ) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm pioneered the first FDA-approved oncolytic immunotherapy -- a neoantigen vaccine specific for patients tumors. This is a… read more...

Trump Protection For Pfizer

via: SeekingAlpha at 2018-07-10 03:42:18:000

CNBC reports on Trump's Pfizer tweet (via CNBC ). Trump Threatens Pfizer President Trump lashed out at Pfizer ( PFE ) by name, and other pharmaceutical companies, in the tweet below on Monday. Given the President's threatened response there, I'll post a couple of ways Pfizer lo… read more...

Dividend Income Update: June 2018

via: SeekingAlpha at 2018-07-09 06:45:01:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alzheimer's players in the green on Biogen news

via: SeekingAlpha at 2018-07-06 10:12:33:000

Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

A Real Dividend Growth Machine: Q2 2018 Portfolio Review

via: SeekingAlpha at 2018-07-05 03:47:22:000

Introduction The purpose of this article is to review my investing progress in the second quarter of 2018. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay and grow their dividends. My long-term in… read more...

Nick's Picks Halftime Report: Beating The Market Once Again

via: SeekingAlpha at 2018-07-05 01:26:32:000

Its the 4 th of July, the heat has died down, the grill has been cleaned, and the fireworks are over with. Ive decided to spend the rest of my evening putting together a halftime report for my annual Nicks Picks portfolio. Its worth noting that its not … read more...

The R.I.P. Portfolio: Q2 2018 Update

via: SeekingAlpha at 2018-07-04 03:25:42:000

The Retire In Peace portfolio , or R.I.P. portfolio , was first introduced to the Seeking Alpha ("SA") community in December 2015 and I have published quarterly articles that captured the activity and performance of the portfolio since that point in time. The companies that I write about o… read more...

Rose Portfolio 93 Stock Cost Per Share Revealed In The First Half And Q2 2018 Report

via: SeekingAlpha at 2018-07-03 11:17:50:000

The Rose Portfolio 93 investments in the Rose portfolio and all golden to me, while chosen with utmost care and consideration for quality and dividend reliability. In a previous article here , I discuss S&P credit ratings and consistency of dividend raises. These traits are importa… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

FDA withdraws draft guidance related to biosimilar development

via: SeekingAlpha at 2018-07-02 12:59:00:000

The FDA has withdrawn its draft guidance on statistical methods to assess analytical similarity between biosimilars and reference drugs after receiving public comments and a lone citizen petition from Pharmaceutical Scientist founder Sarfaraz Niazi, an adjunct professor at the University o… read more...

Venture Capital Deals Of The Week: SoftBank Leads $200M Into Indian Insurance

via: SeekingAlpha at 2018-06-30 10:13:00:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Indian digital insurance: SoftBanks ([[SFTBF]], [[SFTBY]]) Vision Fund led a $200M round in Indian… read more...

Venture Capital Deals Of The Week: SoftBank Leads $200M Into Indian Insurance

via: SeekingAlpha at 2018-06-30 10:13:00:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Indian digital insurance: SoftBanks ([[SFTBF]], [[SFTBY]]) Vision Fund led a $200M round in Indian… read more...

Your Daily Pharma Scoop: FDA Approval For Array, Edge Zooms, Summit Nosedives

via: SeekingAlpha at 2018-06-29 02:48:28:000

Stocks in News: ARRY, EDGE Array BioPharma gets FDA approval for melanoma combo treatment; shares halted Discussion : Array Biopharmas ( ARRY ) combo treatment of encorafenib and binimetinib for patients with advanced melanoma associated with a BRAF mutation receives FDA appro… read more...

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig(TM) (erenumab-aooe) In Patients With Chronic And Episodic Migraine

via: PR Newswire at 2018-06-28 16:30:00:000

THOUSAND OAKS, Calif. , June 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of Aimovig (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at th… read more...

Entera Bio Aims Lower For Improved IPO Terms

via: SeekingAlpha at 2018-06-28 16:16:25:000

Quick Take Entera Bio ( ENTX ) intends to raise $12 million in an IPO from the sale of its common stock and warrants. The firm is developing a pipeline of drugs utilizing its proprietary large molecule oral drug delivery modalities. ENTX has significantly improved the terms of its IP… read more...

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers

via: PR Newswire at 2018-06-27 17:00:00:000

THOUSAND OAKS , Calif.andSAN DIEGO, June 27, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help improve health and well-being in the workplace for people… read more...

Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month

via: PR Newswire at 2018-06-27 16:30:00:000

THOUSAND OAKS, Calif. , June 27, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced initial findings from a large global migraine patient survey, involving more than 11,000 people from 31 countries, including the U.S. The findings, to be presented at the 60th Annual Scientific … read more...

Amgen says infliximab biosimilar candidate data confirm non-inferiority

via: SeekingAlpha at 2018-06-27 09:33:45:000

Amgen ( AMGN +0.5% ) says Phase 3 top-line data shows biosimilar candidate ABP 710 confirms non-inferiority compared with Remicade infliximab but could not rule out superiority on its primary efficacy endpoint. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

via: PR Newswire at 2018-06-27 09:00:00:000

THOUSAND OAKS, Calif. , June 27, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE (infliximab) in patients with moderate-to-severe rheumatoid arthrit… read more...

59 Top-Yield Healthcare Equities For June

via: SeekingAlpha at 2018-06-26 05:02:46:000

Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a… read more...

The Best Dividend-Paying Biotech Stocks For Your Portfolio

via: SeekingAlpha at 2018-06-25 11:41:16:000

Biopharma and Dividends Biotechnology and Pharmaceutical stocks often grab headlines over spectacular clinical successes or failures that send the price soaring (in either direction!). Indeed, the sector is ripe with speculation trying to find the next multi-billion dollar drug. A consequenc… read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

via: PR Newswire at 2018-06-23 08:00:00:000

THOUSAND OAKS, Calif. , June 23, 2018 /PRNewswire/ --Amgen(NASDAQ:AMGN) today announced new data that show Repatha (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with T… read more...

New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

via: PR Newswire at 2018-06-23 08:00:00:000

THOUSAND OAKS, Calif. , June 23, 2018 /PRNewswire/ --Amgen(NASDAQ:AMGN) today announced new data that show Repatha (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with T… read more...

Roche sues Amgen over Herceptin biosimilar

via: SeekingAlpha at 2018-06-22 13:48:01:000

According to the suit filed by Roche's ( OTCQX:RHHBY +2.4% ) Genentech unit, Amgen's ( AMGN -0.2% ) proposed biosimilar of the Herceptin breast cancer drug would infringe on 37 patents. More news on: Roche Holding Ltd ADR, Amgen Inc., Healthcare stocks news, Stocks on the move, … read more...

Arrowhead Pharmaceuticals - Pullbacks Are Becoming Rare, So Take Advantage If You Love The Potential

via: SeekingAlpha at 2018-06-22 13:31:09:000

Arrowhead Pharmaceuticals ( ARWR ) has had a terrific run this last year as it has fully turned the corner from its DPC platform crash and has flourished under its new TRiM platform. Its lead programs might be able to progress through the clinic quicker than investors expect, and its list of c… read more...

3 Calls 3 Different Reasons

via: SeekingAlpha at 2018-06-22 02:03:52:000

Calls are the oddest things. Sometimes you need an up market to get good premiums. Other times, like this week, you can get good premiums during a down trend. You should not sell calls on your coveted income stock willy nilly. You need a reason. Sell calls on stocks when fundamentals such … read more...

Neon Therapeutics Firms Its Plan For $100 Million IPO

via: SeekingAlpha at 2018-06-21 15:22:14:000

Quick Take Neon Therapeutics ( NTGN ) intends to sell 6.25 million shares for gross proceeds of $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm is a clinical-stage immuno-oncology company focused on neoantigen-targeted therapies. The company desires… read more...

Amgen Should Rebound On Aimovig And Kyprolis Revenue

via: SeekingAlpha at 2018-06-20 12:13:58:000

Amgen (AMGN) is a large-cap biotech company, in fact, one of the original biotechs. It pays a dividend, which is rare among biotechs. It also has an extensive pipeline that should offset its patent cliffs and return it to being a growth stock. For the negatives of Amgen that I do not cover i… read more...

EC grants full approval for Amgen's Blincyto

via: SeekingAlpha at 2018-06-19 09:23:04:000

Based on overall survival (OS) data from the Phase 3 TOWER study, the European (EC) has granted full approval for Amgen's (NASDAQ: AMGN ) BLINCYTO (blinatumomab) for the treatment of adult patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblast… read more...

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label

via: PR Newswire at 2018-06-19 09:00:00:000

THOUSAND OAKS, Calif. , June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patien… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

FDA OKs Mylan and Biocon's generic Neulasta

via: SeekingAlpha at 2018-06-14 17:01:46:000

The FDA approves Mylan N.V. (NASDAQ: MYL ) and development partner Biocon's Fulphila (pegfilgrastim-jmbd), a biosimilar of Amgen's (NASDAQ: AMGN ) Neulasta. More news on: Mylan Inc, Amgen Inc., Healthcare stocks news, Read more … read more...

Autolus Therapeutics Readies $125 Million U.S. IPO

via: SeekingAlpha at 2018-06-14 11:26:47:000

Quick Take Autolus Therapeutics Ltd. ( AUTL ) intends to raise $125 million in IPO gross proceeds from the sale of ADSs (American Depositary Receipts), per a registration statement . The company is developing a pipeline of blood cancer and solid tumor T cell treatments with advanced pro… read more...

Companies Receive Enormous Cash Influx In The Form Of Repatriated Cash

via: SeekingAlpha at 2018-06-13 23:48:57:000

By Tortoise Senior Portfolio Manager, Greg Haendel For most of us, tax day came and went on April 17 th . If you are one of the fortunate folks who received a tax refund, did you use the money to pay down debt, save it, invest in home improvement projects, or purchase discretionary or… read more...

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

via: SeekingAlpha at 2018-06-13 17:32:45:000

Over the last year, Mylan ( MYL ) has faced a difficult generic environment but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex-US business that has helped stabilize the business. The key topics around the stock are now: 1) Neulasta biosimilar appro… read more...

3 Things In Biotech, June 12: MET Targeting Gets On Your Radar

via: SeekingAlpha at 2018-06-13 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

May Update For My 92 Investment Rose Portfolio With Bonus Add On Future Purchasing Evaluation Plan

via: SeekingAlpha at 2018-06-12 11:06:53:000

The Rose portfolio The Rose Portfolio consists of 2 Roths, a taxable trust account and 9 separate company stocks outside of the broker. It now sits at 92 Investments and on average ~4.6% dividend yield on value. I hope to do a quarterly report at the end of June for portfolio value and divid… read more...

Advaxis Makes A Bold Strategic Move, Was There A Major Logical Reason Behind It?

via: SeekingAlpha at 2018-06-11 11:50:31:000

Recently, Advaxis ( ADXS ) announced plans to restructure its organization . The reason for the restructuring is to get things back on track for the biotech so that it can capitalize on its pipeline. It intends to change a few of the programs, but I believe it's for a very good reason. That… read more...

Early-stage study of Advaxis' cancer candidate ADXS-NEO underway

via: SeekingAlpha at 2018-06-11 10:27:46:000

The first patient has been dosed in a Phase 1 clinical tria l assessing Advaxis' ( ADXS ) ADXS-NEO, a personalized immunotherapy targeting cancer neoantigens, in patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squam… read more...

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

via: PR Newswire at 2018-06-11 09:00:00:000

THOUSAND OAKS, Calif. , June 11, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S… read more...

45 'Safer' Dividend Nasdaq Equities For June

via: SeekingAlpha at 2018-06-11 02:12:25:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 12.5% to 45% Gains By June, 2019 Three of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were found among the top ten gainers for the coming… read more...

Your 52 Top Yield, Upside And Gains Nasdaq Index Stocks For June

via: SeekingAlpha at 2018-06-09 23:35:17:000

Actionable Conclusions (1-10): Brokers Predict 19% To 45% Net Gains From June's NASDAQ Top Ten Three of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the c… read more...

Has A New Advaxis Awakened Out Of The Doldrums?

via: SeekingAlpha at 2018-06-08 16:38:09:000

Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti… read more...

Has A New Advaxis Awakened Out Of The Doldrums?

via: SeekingAlpha at 2018-06-08 16:38:09:000

Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti… read more...

EC OK's new use for Amgen's Prolia

via: SeekingAlpha at 2018-06-08 09:22:59:000

As expected, the European Commission approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. More news on: Amgen Inc., Healthcare stocks news, … read more...

EC OK's new use for Amgen's Prolia

via: SeekingAlpha at 2018-06-08 09:22:59:000

As expected, the European Commission approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. More news on: Amgen Inc., Healthcare stocks news, … read more...

European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-06-08 09:00:00:000

THOUSAND OAKS, Calif. , June 8, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the European Commission (EC) has approved a new indication forProlia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy i… read more...

European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-06-08 09:00:00:000

THOUSAND OAKS, Calif. , June 8, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the European Commission (EC) has approved a new indication forProlia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy i… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-07 16:00:00:000

THOUSAND OAKS, Calif. , June 7, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday , June 12, 2018, in Rancho Palos Verdes, Calif. Elliott M. Levy , M.D., senior vice president of Resear… read more...

ElectroCore Readies $65 Million U.S. IPO Plans

via: SeekingAlpha at 2018-06-07 14:48:43:000

Quick Take ElectroCore ( ECOR ) intends to raise $65 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is preparing to commercialize a device that promises to treat various forms of headaches. ECOR has a promising, non-invasive treatment op… read more...

This One Study Could Radically Change The Cancer Immunotherapy Market

via: SeekingAlpha at 2018-06-07 10:22:51:000

This year's American Society of Clinical Oncology ((ASCO)) conference in Chicago was chock full of the latest in cancer research and advances, but one retrospective study in particular could help radically change the way cancer immunotherapy trials are conducted going forward. The change cou… read more...

3 Things In Biotech, June 6: Pegfilgrastim Rules The Day

via: SeekingAlpha at 2018-06-07 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription ? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes

via: PR Newswire at 2018-06-06 16:00:00:000

THOUSAND OAKS, Calif. and OKLAHOMA CITY , June 6, 2018 /PRNewswire/ --The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC)and Amgen (NASDAQ:AMGN) today announced a new collaborative agreement to help improve clinical outcomes, experience and satis… read more...

PBMs one-up drug makers on drug copay assistance schemes

via: SeekingAlpha at 2018-06-06 11:41:10:000

Reuters reports that U.S. drug prices fell 5.6% in Q1, 3.6% more than a year ago. Sector & Sovereign analyst Richard Evans believes most of the decline is from "copay accumulator" programs instituted by pharmacy benefit managers (PBMs) last quarter that do not allow copay assistance pa… read more...

3 Things In Biotech, June 5: Roche's Very Bad Day

via: SeekingAlpha at 2018-06-06 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Charts point to big biotech breakout

via: CNBC at 2018-06-04 17:26:00:000

No summary available. read more...

Charts point to big biotech breakout

via: CNBC at 2018-06-04 17:26:00:000

No summary available. read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race

via: SeekingAlpha at 2018-06-03 16:23:53:000

Neulasta , a long-acting version of Amgens Neupogen (filgrastim), is a blockbuster biologic medicine used by cancer patients on chemotherapy to fight off infections. Neulasta brought in ~ $4.7B in revenue for Amgen ( AMGN ) in 2017. Around 87% of the revenue comes from US market an… read more...

Your Daily Pharma Scoop: ScPharma Slumps, Sellas Surges And Zymeworks Trading Suspended

via: SeekingAlpha at 2018-06-02 18:00:00:000

Analysis Focus:SCPH ScPharma (SCPH) was part of almost every stock news column (including ours ) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, … read more...

Your Daily Pharma Scoop: ScPharma Slumps, Sellas Surges And Zymeworks Trading Suspended

via: SeekingAlpha at 2018-06-02 18:00:00:000

Analysis Focus:SCPH ScPharma (SCPH) was part of almost every stock news column (including ours ) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, … read more...

Your Daily Pharma Scoop: ScPharma Slumps, Sellas Surges And Zymeworks Trading Suspended

via: SeekingAlpha at 2018-06-02 18:00:00:000

Analysis Focus:SCPH ScPharma (SCPH) was part of almost every stock news column (including ours ) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, … read more...

Your Daily Pharma Scoop: ScPharma Slumps, Sellas Surges And Zymeworks Trading Suspended

via: SeekingAlpha at 2018-06-02 18:00:00:000

Analysis Focus:SCPH ScPharma (SCPH) was part of almost every stock news column (including ours ) yesterday for its massive slump of ~30% in a single day. Today we come back to focus our discussion on the stock while the slide continues further. Yesterday it touched its 52 wk low at $8.5, … read more...

3 Things In Biotech, June 1: Biosimilars Take Center Stage

via: SeekingAlpha at 2018-06-02 07:56:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today,"… read more...

3 Things In Biotech, June 1: Biosimilars Take Center Stage

via: SeekingAlpha at 2018-06-02 07:56:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today,"… read more...

3 Things In Biotech, June 1: Biosimilars Take Center Stage

via: SeekingAlpha at 2018-06-02 07:56:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today,"… read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

'Big Dog' Biotech Roche Makes Progress: Will The Stock Notice?

via: SeekingAlpha at 2018-06-02 00:08:40:000

Introduction Roche ADRs ( RHHBY ) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December's US tax legislation…. read more...

Once-weekly Kyrolis beats twice-weekly regimen in late-stage MM study

via: SeekingAlpha at 2018-06-01 16:44:50:000

Preliminary results from a Phase 3 clinical trial, A.R.R.O.W ., assessing a once-weekly regimen (70 mg/m 2 ) of Amgen's (NASDAQ: AMGN ) KYPROLIS (carfilzomib) plus dexamethasone in patients with treatment-resistant multiple myeloma (MM) showed a treatment benefit compared to the twice-we… read more...

Once-weekly Kyrolis beats twice-weekly regimen in late-stage MM study

via: SeekingAlpha at 2018-06-01 16:44:50:000

Preliminary results from a Phase 3 clinical trial, A.R.R.O.W ., assessing a once-weekly regimen (70 mg/m 2 ) of Amgen's (NASDAQ: AMGN ) KYPROLIS (carfilzomib) plus dexamethasone in patients with treatment-resistant multiple myeloma (MM) showed a treatment benefit compared to the twice-we… read more...

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

via: PR Newswire at 2018-06-01 16:00:00:000

THOUSAND OAKS, Calif. , June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered … read more...

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma

via: PR Newswire at 2018-06-01 16:00:00:000

THOUSAND OAKS, Calif. , June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered … read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

Amgen's biosimilar for Herceptin fails to win FDA approval

via: SeekingAlpha at 2018-06-01 13:25:31:000

Amgen ( AMGN +2.5% ) has received a CRL from the FDA for its Biologics License Application for ABP 980, a biosimilar to Roche's ( OTCQX:RHHBY +2.1% ) Herceptin. More news on: Amgen Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Amgen's biosimilar for Herceptin fails to win FDA approval

via: SeekingAlpha at 2018-06-01 13:25:31:000

Amgen ( AMGN +2.5% ) has received a CRL from the FDA for its Biologics License Application for ABP 980, a biosimilar to Roche's ( OTCQX:RHHBY +2.1% ) Herceptin. More news on: Amgen Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Portola Pharmaceuticals: Compelling Buyout Target

via: SeekingAlpha at 2018-06-01 11:58:15:000

Most investors are lucky to catch a biotech company before price action explodes on approval of a blockbuster drug. Portola Pharmaceuticals ( PTLA ) is now trading at pre-approval price after gaining approval of two blockbuster drugs. The share price is undervalued and approaching an inflectio… read more...

Portola Pharmaceuticals: Compelling Buyout Target

via: SeekingAlpha at 2018-06-01 11:58:15:000

Most investors are lucky to catch a biotech company before price action explodes on approval of a blockbuster drug. Portola Pharmaceuticals ( PTLA ) is now trading at pre-approval price after gaining approval of two blockbuster drugs. The share price is undervalued and approaching an inflectio… read more...

Amgen inks two oncology collaboration agreements with MD Anderson

via: SeekingAlpha at 2018-05-31 16:16:19:000

Amgen (NASDAQ: AMGN ) announces two multiyear collaboration agreements with MD Anderson Cancer Center to evaluate up to 16 candidates from the company's BiTE, CAR T and small molecule programs. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen inks two oncology collaboration agreements with MD Anderson

via: SeekingAlpha at 2018-05-31 16:15:06:000

Amgen (NASDAQ: AMGN ) announces two multiyear collaboration agreements with MD Anderson Cancer Center to evaluate up to 16 candidates from the company's BiTE, CAR T and small molecule programs. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen inks two oncology collaboration agreements with MD Anderson

via: SeekingAlpha at 2018-05-31 16:13:56:000

Amgen (NASDAQ: AMGN ) announces two multiyear collaboration agreements with MD Anderson Cancer Center to evaluate up to 16 candidates from the company's BiTE, CAR T and small molecule programs. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

via: SeekingAlpha at 2018-05-31 16:08:11:000

Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers

via: PR Newswire at 2018-05-31 16:00:00:000

THOUSAND OAKS, Calif. and HOUSTON , May 31, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology ther… read more...

deCODE genetics Reveals: The Making of a Human Population Uncovered Through Ancient Icelandic Genomes

via: PR Newswire at 2018-05-31 14:00:00:000

REYKJAVIK, Iceland , May 31, 2018 /PRNewswire/ -- In a study published today, scientists at deCODE genetics report new findings about the founding of the Icelandic population and its subsequent evolution, based on ancient DNA. The study appears today in the online edition of Science … read more...

deCODE genetics Reveals: The Making of a Human Population Uncovered Through Ancient Icelandic Genomes

via: PR Newswire at 2018-05-31 14:00:00:000

REYKJAVIK, Iceland , May 31, 2018 /PRNewswire/ -- In a study published today, scientists at deCODE genetics report new findings about the founding of the Icelandic population and its subsequent evolution, based on ancient DNA. The study appears today in the online edition of Science … read more...

Pick Up Amgen In 2018

via: SeekingAlpha at 2018-05-31 13:40:53:000

Today, investors view Amgen ( AMGN ) as a struggling biotechnology firm, with its upcoming patent expiries, competitive pressures, ongoing litigations, R&D failures, slow commercial launches, and many more concerns. It, however, needs to be realized that these problems do not define this o… read more...

Amgen Has Me Worried Therefore Selling Calls

via: SeekingAlpha at 2018-05-31 06:36:12:000

I have held Amgen (AMGN), the pharmaceutical company, since 2017. I am getting a bit nervous about this dividend growth stock. When I get nervous, but the stock is still doing well, I sell calls that are close to the current price but fetch a big premium. Dividend Growth alone is not enoug… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen

via: SeekingAlpha at 2018-05-23 17:01:59:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen to collaborate on patient-centric cancer management initiative

via: SeekingAlpha at 2018-05-23 16:14:16:000

Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

via: PR Newswire at 2018-05-23 16:00:00:000

THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen… read more...

Your Daily Pharma Scoop: Sesen Bio Presents Vicinium Data, UroGen's Mitogel Data, FibroGen In IPF

via: SeekingAlpha at 2018-05-22 18:00:00:000

Analysis focus: SESN Sesen Bio (SESN) is a nanocap that has managed to get a drug through a phase 3 study. Not only that, but it has managed to come up with positive data for its lead antibody-drug conjugate (ADC) Vicinium in patients with high-grade non-muscle invasive bladder cancer (NMI… read more...

Your Daily Pharma Scoop: Sesen Bio Presents Vicinium Data, UroGen's Mitogel Data, FibroGen In IPF

via: SeekingAlpha at 2018-05-22 18:00:00:000

Analysis focus: SESN Sesen Bio (SESN) is a nanocap that has managed to get a drug through a phase 3 study. Not only that, but it has managed to come up with positive data for its lead antibody-drug conjugate (ADC) Vicinium in patients with high-grade non-muscle invasive bladder cancer (NMI… read more...

Your Daily Pharma Scoop: Sesen Bio Presents Vicinium Data, UroGen's Mitogel Data, FibroGen In IPF

via: SeekingAlpha at 2018-05-22 18:00:00:000

Analysis focus: SESN Sesen Bio (SESN) is a nanocap that has managed to get a drug through a phase 3 study. Not only that, but it has managed to come up with positive data for its lead antibody-drug conjugate (ADC) Vicinium in patients with high-grade non-muscle invasive bladder cancer (NMI… read more...

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

via: PR Newswire at 2018-05-22 16:45:00:000

THOUSAND OAKS, Calif. , May 22, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif.Approximately90 percent of outstanding shares were represented at the meeting. … read more...

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

via: PR Newswire at 2018-05-22 16:45:00:000

THOUSAND OAKS, Calif. , May 22, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif.Approximately90 percent of outstanding shares were represented at the meeting. … read more...

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

via: PR Newswire at 2018-05-22 16:45:00:000

THOUSAND OAKS, Calif. , May 22, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif.Approximately90 percent of outstanding shares were represented at the meeting. … read more...

Entera Bio Re-Enters IPO Process

via: SeekingAlpha at 2018-05-22 14:07:11:000

Quick Take Entera Bio ( ENTX ) has filed an amended F-1/A registration statement and now intends to sell units consisting of stock and warrants. The company is developing a pipeline of treatments for hypoparathyroidism and osteoporosis. ENTX management appears to be sweetening previo… read more...

Entera Bio Re-Enters IPO Process

via: SeekingAlpha at 2018-05-22 14:07:11:000

Quick Take Entera Bio ( ENTX ) has filed an amended F-1/A registration statement and now intends to sell units consisting of stock and warrants. The company is developing a pipeline of treatments for hypoparathyroidism and osteoporosis. ENTX management appears to be sweetening previo… read more...

Entera Bio Re-Enters IPO Process

via: SeekingAlpha at 2018-05-22 14:07:11:000

Quick Take Entera Bio ( ENTX ) has filed an amended F-1/A registration statement and now intends to sell units consisting of stock and warrants. The company is developing a pipeline of treatments for hypoparathyroidism and osteoporosis. ENTX management appears to be sweetening previo… read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA OKs new indication for Amgen's Prolia

via: SeekingAlpha at 2018-05-21 16:12:16:000

The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

via: PR Newswire at 2018-05-21 16:00:00:000

THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h… read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow

via: SeekingAlpha at 2018-05-21 13:21:41:000

The following slide deck was published by Amgen Inc. in conjunction with this Read more … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

The Next Generation Dividend Growth Portfolio Q1 Update - Bring On The Dividends

via: SeekingAlpha at 2018-05-21 11:49:46:000

Welcome to the first progress report on the progress of the Next Generation Dividend Growth Portfolio. I will also apologize for not getting this out sooner but as readers of my other model portfolio have learned, I have been working on a spreadsheet that would calculate the dividends and the … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

via: SeekingAlpha at 2018-05-21 10:00:00:000

Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?

via: SeekingAlpha at 2018-05-21 04:00:33:000

Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

via: CNBC at 2018-05-18 17:39:00:000

No summary available. read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

J&J bails on Alzheimer's candidate atabecestat on toxicity issues

via: SeekingAlpha at 2018-05-18 12:03:36:000

Johnson & Johnson ( JNJ +0.4% ) unit Janssen has decided to terminate its Phase 2b/3 clinical trial, EARLY , and a Phase 2 long-term safety study evaluating BACE inhibitor atabecestat for slowing the rate of cognitive decline in patients with preclinical Alzheimer's disease (AD). … read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

via: SeekingAlpha at 2018-05-18 10:00:00:000

Analysis focus: RARE Ultragenyx (RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; a… read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Amgen's first mover advantage with Aimovig bodes well - analysts

via: SeekingAlpha at 2018-05-18 08:42:33:000

As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

FDA OKs Amgen and Novartis' migraine med Aimovig

via: SeekingAlpha at 2018-05-18 07:05:48:000

Amgen (NASDAQ: AMGN ) and collaboration partner Novartis (NYSE: NVS ) announce that the FDA has approved Aimovig (erenumab-aooe) for the prevention of migraine in adults. More news on: Amgen Inc., Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Amgen and Novartis' migraine med Aimovig

via: SeekingAlpha at 2018-05-18 07:05:48:000

Amgen (NASDAQ: AMGN ) and collaboration partner Novartis (NYSE: NVS ) announce that the FDA has approved Aimovig (erenumab-aooe) for the prevention of migraine in adults. More news on: Amgen Inc., Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Amgen and Novartis' migraine med Aimovig

via: SeekingAlpha at 2018-05-18 07:05:48:000

Amgen (NASDAQ: AMGN ) and collaboration partner Novartis (NYSE: NVS ) announce that the FDA has approved Aimovig (erenumab-aooe) for the prevention of migraine in adults. More news on: Amgen Inc., Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Amgen and Novartis' migraine med Aimovig

via: SeekingAlpha at 2018-05-18 07:05:48:000

Amgen (NASDAQ: AMGN ) and collaboration partner Novartis (NYSE: NVS ) announce that the FDA has approved Aimovig (erenumab-aooe) for the prevention of migraine in adults. More news on: Amgen Inc., Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

The MnM Portfolio - Reviewing May 2018 Fundamentals

via: SeekingAlpha at 2018-05-18 02:52:16:000

My Fundamental Review Process Its been about three months since I last reported on the fundamentals of the stocks in my MnM Portfolio. Periodically, I review my portfolios holdings to take stock of how my holdings are doing and to assist with the allocation of incoming d… read more...

The MnM Portfolio - Reviewing May 2018 Fundamentals

via: SeekingAlpha at 2018-05-18 02:52:16:000

My Fundamental Review Process Its been about three months since I last reported on the fundamentals of the stocks in my MnM Portfolio. Periodically, I review my portfolios holdings to take stock of how my holdings are doing and to assist with the allocation of incoming d… read more...

The MnM Portfolio - Reviewing May 2018 Fundamentals

via: SeekingAlpha at 2018-05-18 02:52:16:000

My Fundamental Review Process Its been about three months since I last reported on the fundamentals of the stocks in my MnM Portfolio. Periodically, I review my portfolios holdings to take stock of how my holdings are doing and to assist with the allocation of incoming d… read more...

The MnM Portfolio - Reviewing May 2018 Fundamentals

via: SeekingAlpha at 2018-05-18 02:52:16:000

My Fundamental Review Process Its been about three months since I last reported on the fundamentals of the stocks in my MnM Portfolio. Periodically, I review my portfolios holdings to take stock of how my holdings are doing and to assist with the allocation of incoming d… read more...

FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention

via: PR Newswire at 2018-05-17 19:04:00:000

THOUSAND OAKS, Calif. , May 17, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe)for thepreventive treatment of migraine in adults. Aimovig is a novel therapeutic approac… read more...

FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention

via: PR Newswire at 2018-05-17 19:04:00:000

THOUSAND OAKS, Calif. , May 17, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe)for thepreventive treatment of migraine in adults. Aimovig is a novel therapeutic approac… read more...

FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention

via: PR Newswire at 2018-05-17 19:04:00:000

THOUSAND OAKS, Calif. , May 17, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe)for thepreventive treatment of migraine in adults. Aimovig is a novel therapeutic approac… read more...

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

via: SeekingAlpha at 2018-05-17 12:00:00:000

Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following... read more...

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

via: SeekingAlpha at 2018-05-17 12:00:00:000

Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following... read more...

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

via: SeekingAlpha at 2018-05-17 12:00:00:000

Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following... read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Eli Lilly Had Good Reason To Spend $1.6B On Armo

via: SeekingAlpha at 2018-05-16 11:24:22:000

Eli Lillys ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Expanded label for Amgen's Repatha approved in Europe

via: SeekingAlpha at 2018-05-16 09:18:39:000

The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

via: PR Newswire at 2018-05-16 09:00:00:000

THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With

via: SeekingAlpha at 2018-05-16 07:38:26:000

Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA OKs Pfizer's Epogen/Procrit biosimilar

via: SeekingAlpha at 2018-05-15 12:06:37:000

The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...

Oryzon Genomics commences mid-stage study of Alzheimer's candidate

via: SeekingAlpha at 2018-05-14 12:27:31:000

Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...

Venture Capital Deals Of The Week: E-Trade Competitor Hits $5.6B Valuation

via: SeekingAlpha at 2018-05-12 11:02:14:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Free stock trading: E*Trade (ETFC) competitor Robinhood raised $363M in a Series D round that brought valuatio… read more...

Venture Capital Deals Of The Week: E-Trade Competitor Hits $5.6B Valuation

via: SeekingAlpha at 2018-05-12 11:02:14:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Free stock trading: E*Trade (ETFC) competitor Robinhood raised $363M in a Series D round that brought valuatio… read more...

Get Rich (Safely) With Growth Strategies: 3 To Consider

via: SeekingAlpha at 2018-05-12 09:00:00:000

Most of our articles are based on conservative or income-oriented strategies; however, this article is a bit of an outlier and focused on investing in fast-growing companies. Needless to say, one should expect higher risk and higher volatility from any such strategy in return for outsized perf… read more...

Trump speech on drug prices light on specifics

via: SeekingAlpha at 2018-05-11 14:25:19:000

Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First: More news on: Health Care Select Sect SPDR ETF, Vanguard Health Care ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

via: PR Newswire at 2018-02-14 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO (blinatumomab) supplemental Biologics License Applicat… read more...

NASDAQ 'Safer' Dividend Gainers Led By Lam, Western, Broadcom & Vodafone, Per February Broker Targets

via: SeekingAlpha at 2018-02-13 12:50:38:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 19.39% to 47.09% Gains By February, 2019 Two of the ten top yield "safer" Dividend NASDAQ stocks (see names tinted grey in the list above) were found among the top ten gainers for the coming… read more...

NASDAQ 'Safer' Dividend Gainers Led By Lam, Western, Broadcom & Vodafone, Per February Broker Targets

via: SeekingAlpha at 2018-02-13 12:50:38:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 19.39% to 47.09% Gains By February, 2019 Two of the ten top yield "safer" Dividend NASDAQ stocks (see names tinted grey in the list above) were found among the top ten gainers for the coming… read more...

NASDAQ 'Safer' Dividend Gainers Led By Lam, Western, Broadcom & Vodafone, Per February Broker Targets

via: SeekingAlpha at 2018-02-13 12:50:38:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 19.39% to 47.09% Gains By February, 2019 Two of the ten top yield "safer" Dividend NASDAQ stocks (see names tinted grey in the list above) were found among the top ten gainers for the coming… read more...

Western Digital Gain And Vodafone Yield Set Highest Marks For Nasdaq Dividend Stocks To February 2019

via: SeekingAlpha at 2018-02-13 09:40:16:000

Actionable Conclusions (1-10): Brokers Predicted 21.85% To 38.96 % Net Gains From February Top Ten Only two of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the… read more...

Western Digital Gain And Vodafone Yield Set Highest Marks For Nasdaq Dividend Stocks To February 2019

via: SeekingAlpha at 2018-02-13 09:40:16:000

Actionable Conclusions (1-10): Brokers Predicted 21.85% To 38.96 % Net Gains From February Top Ten Only two of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the… read more...

Western Digital Gain And Vodafone Yield Set Highest Marks For Nasdaq Dividend Stocks To February 2019

via: SeekingAlpha at 2018-02-13 09:40:16:000

Actionable Conclusions (1-10): Brokers Predicted 21.85% To 38.96 % Net Gains From February Top Ten Only two of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the… read more...

Teva's Luck Continues To Run Out

via: SeekingAlpha at 2018-02-12 15:14:57:000

Teva ( TEVA ) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continue… read more...

Teva's Luck Continues To Run Out

via: SeekingAlpha at 2018-02-12 15:14:57:000

Teva ( TEVA ) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continue… read more...

Teva's Luck Continues To Run Out

via: SeekingAlpha at 2018-02-12 15:14:57:000

Teva ( TEVA ) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continue… read more...

Teva Or Amgen/Novartis, Who Will Win The Battle For Migraine Market Share?

via: SeekingAlpha at 2018-02-12 07:49:20:000

Teva Pharmaceuticals ( TEVA ) and Amgen ( AMGN ) both have important dates with the FDA for their new migraine drugs this year, both expected to be blockbuster. Amgens PDUFA date, partnered with Novartis ( NVS ), is in May, and Tevas is one month later in June. Both are expecte… read more...

Teva Or Amgen/Novartis, Who Will Win The Battle For Migraine Market Share?

via: SeekingAlpha at 2018-02-12 07:49:20:000

Teva Pharmaceuticals ( TEVA ) and Amgen ( AMGN ) both have important dates with the FDA for their new migraine drugs this year, both expected to be blockbuster. Amgens PDUFA date, partnered with Novartis ( NVS ), is in May, and Tevas is one month later in June. Both are expecte… read more...

Teva Or Amgen/Novartis, Who Will Win The Battle For Migraine Market Share?

via: SeekingAlpha at 2018-02-12 07:49:20:000

Teva Pharmaceuticals ( TEVA ) and Amgen ( AMGN ) both have important dates with the FDA for their new migraine drugs this year, both expected to be blockbuster. Amgens PDUFA date, partnered with Novartis ( NVS ), is in May, and Tevas is one month later in June. Both are expecte… read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Amgen As A Source Of Funds

via: SeekingAlpha at 2018-02-12 06:56:28:000

Background The venerable biotech Amgen ( AMGN ) has been one of the all-time great stock market performers. This stellar performance, which revived after more than a decade of stagnation, when the great bull market post-2011 took off and biotech became the leading subsector of the market, … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Canada's Trudeau makes his pitch for Amazon's second HQ as he tours San Francisco tech scene

via: CNBC at 2018-02-08 20:05:00:000

No summary available. read more...

Canada's Trudeau makes his pitch for Amazon's second HQ as he tours San Francisco tech scene

via: CNBC at 2018-02-08 20:05:00:000

No summary available. read more...

Canada's Trudeau makes his pitch for Amazon's second HQ as he tours San Francisco tech scene

via: CNBC at 2018-02-08 20:05:00:000

No summary available. read more...

Canada's Trudeau makes his pitch for Amazon's second HQ as he tours San Francisco tech scene

via: CNBC at 2018-02-08 20:05:00:000

No summary available. read more...

Canada's Trudeau makes his pitch for Amazon's second HQ as he tours San Francisco tech scene

via: CNBC at 2018-02-08 20:05:00:000

No summary available. read more...

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

via: PR Newswire at 2018-02-08 18:44:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced results from the XGEVA (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were publis… read more...

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

via: PR Newswire at 2018-02-08 18:44:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced results from the XGEVA (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were publis… read more...

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

via: PR Newswire at 2018-02-08 18:44:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced results from the XGEVA (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were publis… read more...

Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference

via: PR Newswire at 2018-02-08 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7 th Annual Leerink Partners Global Healthcare Conference at 10 a.m. ET on Wednesday, Feb. 14, 2018 , in New York City . David W. Meline , executive vice president and chief financial officer … read more...

Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference

via: PR Newswire at 2018-02-08 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7 th Annual Leerink Partners Global Healthcare Conference at 10 a.m. ET on Wednesday, Feb. 14, 2018 , in New York City . David W. Meline , executive vice president and chief financial officer … read more...

Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference

via: PR Newswire at 2018-02-08 16:00:00:000

THOUSAND OAKS, Calif. , Feb. 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7 th Annual Leerink Partners Global Healthcare Conference at 10 a.m. ET on Wednesday, Feb. 14, 2018 , in New York City . David W. Meline , executive vice president and chief financial officer … read more...

Harvard genetics pioneer wants to monetize DNA with digital currency, and defeat 23andMe

via: CNBC at 2018-02-08 14:20:00:000

No summary available. read more...

Harvard genetics pioneer wants to monetize DNA with digital currency, and defeat 23andMe

via: CNBC at 2018-02-08 14:20:00:000

No summary available. read more...

Harvard genetics pioneer wants to monetize DNA with digital currency, and defeat 23andMe

via: CNBC at 2018-02-08 14:20:00:000

No summary available. read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Upcoming Dividends; 75 Companies, 33 Increases, 18 Double Digit Increases!

via: SeekingAlpha at 2018-02-08 09:35:09:000

Introduction The information presented below was created based on combining the "U.S. Dividend Champion" spreadsheet compiled by David Fish hosted here with upcoming dividend information from the Nasdaq . This meshes metrics about companies with dividend growth history with upcoming divid… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Pluristem - Hidden Treasures And Sudden Catalysts

via: SeekingAlpha at 2018-02-08 08:18:13:000

Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d… read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

Democrats slam Republican tax cut for $97 billion wave in corporate share buybacks

via: CNBC at 2018-02-07 14:15:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

In wake of Trump tax bill, companies have raced to buy back their own stock

via: CNBC at 2018-02-07 12:00:00:000

No summary available. read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

24 Dividend Increases: January 29-February 2, 2018 (Part 2: Remaining Sectors)

via: SeekingAlpha at 2018-02-07 07:00:09:000

Companies can only increase their dividends regularly if they grow earnings sufficiently. I monitor dividend increases of stocks in the CCC list of dividend growth stocks. I use the following screens to compile a watch list from the CCC stocks: Market cap $500M No stocks that ar… read more...

My Dividend Growth Portfolio - 46 Holdings, 1 Buy, 2 Sells

via: SeekingAlpha at 2018-02-06 10:29:12:000

Welcome to the January 2018 update for my dividend growth portfolio. The year has started off with a big bang as each company analyzes (and some guide) to how the tax plan will change their upcoming 2018 earnings forecasts. Though recently the market has taken a breather, stocks trade at an el… read more...

My Dividend Growth Portfolio - 46 Holdings, 1 Buy, 2 Sells

via: SeekingAlpha at 2018-02-06 10:29:12:000

Welcome to the January 2018 update for my dividend growth portfolio. The year has started off with a big bang as each company analyzes (and some guide) to how the tax plan will change their upcoming 2018 earnings forecasts. Though recently the market has taken a breather, stocks trade at an el… read more...

My Dividend Growth Portfolio - 46 Holdings, 1 Buy, 2 Sells

via: SeekingAlpha at 2018-02-06 10:29:12:000

Welcome to the January 2018 update for my dividend growth portfolio. The year has started off with a big bang as each company analyzes (and some guide) to how the tax plan will change their upcoming 2018 earnings forecasts. Though recently the market has taken a breather, stocks trade at an el… read more...

3 Things In Biotech You Should Learn Today: February 5, 2017

via: SeekingAlpha at 2018-02-06 08:00:05:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 5, 2017

via: SeekingAlpha at 2018-02-06 08:00:05:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 5, 2017

via: SeekingAlpha at 2018-02-06 08:00:05:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

Spectrum Pharma's Rolontis on par with Neulasta in late-stage study; shares ahead 7% premarket

via: SeekingAlpha at 2018-02-05 07:48:57:000

A Phase 3 clinical trial, ADVANCE , evaluating Spectrum Pharmaceuticals' (NASDAQ: SPPI ) ROLONTIS (eflapegrastim) compared to Amgen's (NASDAQ: AMGN ) Neulasta (pegfilgrastim) in managing chemotherapy-induced neutropenia in patients with early-stage breast cancer met the primary endpoint &#… read more...

Spectrum Pharma's Rolontis on par with Neulasta in late-stage study; shares ahead 7% premarket

via: SeekingAlpha at 2018-02-05 07:48:57:000

A Phase 3 clinical trial, ADVANCE , evaluating Spectrum Pharmaceuticals' (NASDAQ: SPPI ) ROLONTIS (eflapegrastim) compared to Amgen's (NASDAQ: AMGN ) Neulasta (pegfilgrastim) in managing chemotherapy-induced neutropenia in patients with early-stage breast cancer met the primary endpoint &#… read more...

Spectrum Pharma's Rolontis on par with Neulasta in late-stage study; shares ahead 7% premarket

via: SeekingAlpha at 2018-02-05 07:48:57:000

A Phase 3 clinical trial, ADVANCE , evaluating Spectrum Pharmaceuticals' (NASDAQ: SPPI ) ROLONTIS (eflapegrastim) compared to Amgen's (NASDAQ: AMGN ) Neulasta (pegfilgrastim) in managing chemotherapy-induced neutropenia in patients with early-stage breast cancer met the primary endpoint &#… read more...

Weighing Pros And Cons Of Celgene

via: SeekingAlpha at 2018-02-05 05:59:30:000

Introduction I'd like to do something just a little different in this article on Celgene ( CELG ), and present the pros and cons of the stock as I see them following the latest earnings report and conference call . There are 773.5 MM diluted shares outstanding (fourth-quarter average). … read more...

Weighing Pros And Cons Of Celgene

via: SeekingAlpha at 2018-02-05 05:59:30:000

Introduction I'd like to do something just a little different in this article on Celgene ( CELG ), and present the pros and cons of the stock as I see them following the latest earnings report and conference call . There are 773.5 MM diluted shares outstanding (fourth-quarter average). … read more...

Weighing Pros And Cons Of Celgene

via: SeekingAlpha at 2018-02-05 05:59:30:000

Introduction I'd like to do something just a little different in this article on Celgene ( CELG ), and present the pros and cons of the stock as I see them following the latest earnings report and conference call . There are 773.5 MM diluted shares outstanding (fourth-quarter average). … read more...

3 Things In Biotech You Should Learn Today: February 1, 2018

via: SeekingAlpha at 2018-02-02 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 1, 2018

via: SeekingAlpha at 2018-02-02 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 1, 2018

via: SeekingAlpha at 2018-02-02 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 1, 2018

via: SeekingAlpha at 2018-02-02 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: February 1, 2018

via: SeekingAlpha at 2018-02-02 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

Wall Street Breakfast: Sprightly Jobs Growth Anticipated

via: SeekingAlpha at 2018-02-02 07:02:57:000

A rise of 180,000 jobs is anticipated for January, per a Thomson Reuters survey of economists, when the Bureau of Labor Statistics reports the numbers at 8:30 a.m. EST Friday. The figure would represent a jump from last month's 148,000 nonfarm payrolls growth, which widely missed e… read more...

Wall Street Breakfast: Sprightly Jobs Growth Anticipated

via: SeekingAlpha at 2018-02-02 07:02:57:000

A rise of 180,000 jobs is anticipated for January, per a Thomson Reuters survey of economists, when the Bureau of Labor Statistics reports the numbers at 8:30 a.m. EST Friday. The figure would represent a jump from last month's 148,000 nonfarm payrolls growth, which widely missed e… read more...

Wall Street Breakfast: Sprightly Jobs Growth Anticipated

via: SeekingAlpha at 2018-02-02 07:02:57:000

A rise of 180,000 jobs is anticipated for January, per a Thomson Reuters survey of economists, when the Bureau of Labor Statistics reports the numbers at 8:30 a.m. EST Friday. The figure would represent a jump from last month's 148,000 nonfarm payrolls growth, which widely missed e… read more...

Wall Street Breakfast: Sprightly Jobs Growth Anticipated

via: SeekingAlpha at 2018-02-02 07:02:57:000

A rise of 180,000 jobs is anticipated for January, per a Thomson Reuters survey of economists, when the Bureau of Labor Statistics reports the numbers at 8:30 a.m. EST Friday. The figure would represent a jump from last month's 148,000 nonfarm payrolls growth, which widely missed e… read more...

Wall Street Breakfast: Sprightly Jobs Growth Anticipated

via: SeekingAlpha at 2018-02-02 07:02:57:000

A rise of 180,000 jobs is anticipated for January, per a Thomson Reuters survey of economists, when the Bureau of Labor Statistics reports the numbers at 8:30 a.m. EST Friday. The figure would represent a jump from last month's 148,000 nonfarm payrolls growth, which widely missed e… read more...

Amgen's (AMGN) CEO Bob Bradway on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-02 02:08:05:000

Amgen Inc. (AMGN) Q4 2017 Earnings Conference Call February 1, 2018 17:00 ET Executives Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman and Chief Executive Officer David Meline - Chief Financial Officer Tony Hooper - Head, Global Commercial Operations … read more...

Amgen's (AMGN) CEO Bob Bradway on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-02 02:08:05:000

Amgen Inc. (AMGN) Q4 2017 Earnings Conference Call February 1, 2018 17:00 ET Executives Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman and Chief Executive Officer David Meline - Chief Financial Officer Tony Hooper - Head, Global Commercial Operations … read more...

Amgen's (AMGN) CEO Bob Bradway on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-02 02:08:05:000

Amgen Inc. (AMGN) Q4 2017 Earnings Conference Call February 1, 2018 17:00 ET Executives Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman and Chief Executive Officer David Meline - Chief Financial Officer Tony Hooper - Head, Global Commercial Operations … read more...

Amgen's (AMGN) CEO Bob Bradway on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-02 02:08:05:000

Amgen Inc. (AMGN) Q4 2017 Earnings Conference Call February 1, 2018 17:00 ET Executives Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman and Chief Executive Officer David Meline - Chief Financial Officer Tony Hooper - Head, Global Commercial Operations … read more...

Amgen's (AMGN) CEO Bob Bradway on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-02 02:08:05:000

Amgen Inc. (AMGN) Q4 2017 Earnings Conference Call February 1, 2018 17:00 ET Executives Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman and Chief Executive Officer David Meline - Chief Financial Officer Tony Hooper - Head, Global Commercial Operations … read more...

Amgen Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-01 20:10:29:000

The following slide deck was published by Amgen Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Amgen Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-01 20:10:29:000

The following slide deck was published by Amgen Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Amgen Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-01 20:10:29:000

The following slide deck was published by Amgen Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Amgen Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-01 20:10:29:000

The following slide deck was published by Amgen Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Amgen Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-01 20:10:29:000

The following slide deck was published by Amgen Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Amgen Q4 top line off 3%; non-GAAP EPS flat; shares down 5% after hours

via: SeekingAlpha at 2018-02-01 16:15:02:000

Amgen (NASDAQ: AMGN ) Q4 results ($M): Revenues: 5,802 (-2.7%); Product sales: 5,569 (-1.7%). More news on: Amgen Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amgen Q4 top line off 3%; non-GAAP EPS flat; shares down 5% after hours

via: SeekingAlpha at 2018-02-01 16:15:02:000

Amgen (NASDAQ: AMGN ) Q4 results ($M): Revenues: 5,802 (-2.7%); Product sales: 5,569 (-1.7%). More news on: Amgen Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amgen Q4 top line off 3%; non-GAAP EPS flat; shares down 5% after hours

via: SeekingAlpha at 2018-02-01 16:15:02:000

Amgen (NASDAQ: AMGN ) Q4 results ($M): Revenues: 5,802 (-2.7%); Product sales: 5,569 (-1.7%). More news on: Amgen Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Amgen misses by $0.14, misses on revenue

via: SeekingAlpha at 2018-02-01 16:04:06:000

Amgen (NASDAQ: AMGN ): Q4 EPS of $2.89 misses by $0.14 . Revenue of $5.8B (-2.7% Y/Y) misses by $30M . Shares -3.5% . Press Release More news on: Amgen Inc., Earnings news and commentary, Healthcare stocks news, read more...

Amgen misses by $0.14, misses on revenue

via: SeekingAlpha at 2018-02-01 16:04:06:000

Amgen (NASDAQ: AMGN ): Q4 EPS of $2.89 misses by $0.14 . Revenue of $5.8B (-2.7% Y/Y) misses by $30M . Shares -3.5% . Press Release More news on: Amgen Inc., Earnings news and commentary, Healthcare stocks news, read more...

Amgen misses by $0.14, misses on revenue

via: SeekingAlpha at 2018-02-01 16:04:06:000

Amgen (NASDAQ: AMGN ): Q4 EPS of $2.89 misses by $0.14 . Revenue of $5.8B (-2.7% Y/Y) misses by $30M . Shares -3.5% . Press Release More news on: Amgen Inc., Earnings news and commentary, Healthcare stocks news, read more...

Amgen Reports Fourth Quarter And Full Year 2017 Financial Results

via: PR Newswire at 2018-02-01 16:01:00:000

THOUSAND OAKS, Calif. , Feb. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2017. Key results include: For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion . Fo… read more...

Amgen Reports Fourth Quarter And Full Year 2017 Financial Results

via: PR Newswire at 2018-02-01 16:01:00:000

THOUSAND OAKS, Calif. , Feb. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2017. Key results include: For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion . Fo… read more...

Amgen Reports Fourth Quarter And Full Year 2017 Financial Results

via: PR Newswire at 2018-02-01 16:01:00:000

THOUSAND OAKS, Calif. , Feb. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2017. Key results include: For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion . Fo… read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2018-01-31 17:35:05:000

AAPL , ACET , AIV , AMGN , AMZN , ATHN , BKH , BRKS , CPT , CY , DATA , DCT , DECK , EMN , ENVA , EPAY , ESL , EW , EXPO , FBHS , GOOG , GPRO , IIVI , KMT , KRG , LPLA , MAT , MSI , MTX , MWA , NFG , NGVC , OMCL , OSIS , PACB , POST , POWI , RTEC , SIG… read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2018-01-31 17:35:05:000

AAPL , ACET , AIV , AMGN , AMZN , ATHN , BKH , BRKS , CPT , CY , DATA , DCT , DECK , EMN , ENVA , EPAY , ESL , EW , EXPO , FBHS , GOOG , GPRO , IIVI , KMT , KRG , LPLA , MAT , MSI , MTX , MWA , NFG , NGVC , OMCL , OSIS , PACB , POST , POWI , RTEC , SIG… read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2018-01-31 17:35:05:000

AAPL , ACET , AIV , AMGN , AMZN , ATHN , BKH , BRKS , CPT , CY , DATA , DCT , DECK , EMN , ENVA , EPAY , ESL , EW , EXPO , FBHS , GOOG , GPRO , IIVI , KMT , KRG , LPLA , MAT , MSI , MTX , MWA , NFG , NGVC , OMCL , OSIS , PACB , POST , POWI , RTEC , SIG… read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

Big biopharma firms poised to end session in the red after Trump comments on high prices

via: SeekingAlpha at 2018-01-31 15:50:09:000

Large cap biopharma companies continue to be under pressure as the close nears. In last night's State of the Union address, President Trump stated that cutting drug prices is a "top priority." More news on: Johnson & Johnson, AbbVie Inc., Allergan plc, Healthcare stocks news, Stocks … read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

A Happy First Year Anniversary For The Dividend Growth TR Portfolio

via: SeekingAlpha at 2018-01-31 11:10:11:000

Background This portfolio is a variation of a dividend growth portfolio that I managed for 3 years while working for an RIA and represents growth holdings in my personal portfolio. The DGTR portfolio is designed for investors who seek total return and are comfortable with a lower yield th… read more...

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

via: SeekingAlpha at 2018-01-31 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

via: SeekingAlpha at 2018-01-31 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...

European advisory group backs label update for Amgen's Kyprolis

via: SeekingAlpha at 2018-01-30 09:57:32:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting the inclusion of updated overall survival (OS)data from the Phase 3 ENDEAVOR study in multiple myeloma to the label of Amgen's (NASDAQ: AMGN ) KYPROLIS (carfilzo… read more...

European advisory group backs label update for Amgen's Kyprolis

via: SeekingAlpha at 2018-01-30 09:57:32:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting the inclusion of updated overall survival (OS)data from the Phase 3 ENDEAVOR study in multiple myeloma to the label of Amgen's (NASDAQ: AMGN ) KYPROLIS (carfilzo… read more...

European advisory group backs label update for Amgen's Kyprolis

via: SeekingAlpha at 2018-01-30 09:57:32:000

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting the inclusion of updated overall survival (OS)data from the Phase 3 ENDEAVOR study in multiple myeloma to the label of Amgen's (NASDAQ: AMGN ) KYPROLIS (carfilzo… read more...

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

via: PR Newswire at 2018-01-30 09:00:00:000

THOUSAND OAKS, Calif. , Jan. 30, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS (carfilzo… read more...

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

via: PR Newswire at 2018-01-30 09:00:00:000

THOUSAND OAKS, Calif. , Jan. 30, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS (carfilzo… read more...

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

via: PR Newswire at 2018-01-30 09:00:00:000

THOUSAND OAKS, Calif. , Jan. 30, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS (carfilzo… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Embrace The Volatility - Cramer's Mad Money (1/29/18)

via: SeekingAlpha at 2018-01-30 07:38:41:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 29. Cramer cautioned investors to embrace upcoming volatility now that the crux of the earnings season is on. With so many stocks due to report earnings, there will be massive ups and downs, winn… read more...

Cramer's charts forecast further gains for health care giants Centene and Cardinal Health

via: CNBC at 2018-01-29 18:25:00:000

No summary available. read more...

Cramer's charts forecast further gains for health care giants Centene and Cardinal Health

via: CNBC at 2018-01-29 18:25:00:000

No summary available. read more...

Cramer's charts forecast further gains for health care giants Centene and Cardinal Health

via: CNBC at 2018-01-29 18:25:00:000

No summary available. read more...

Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results

via: PR Newswire at 2018-01-29 16:00:00:000

THOUSAND OAKS, Calif. , Jan. 29, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a con… read more...

Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results

via: PR Newswire at 2018-01-29 16:00:00:000

THOUSAND OAKS, Calif. , Jan. 29, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a con… read more...

Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results

via: PR Newswire at 2018-01-29 16:00:00:000

THOUSAND OAKS, Calif. , Jan. 29, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a con… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

Big Pharma Rules 'Safer' Dividend Healthcare Top Gains Per Broker Targets To January

via: SeekingAlpha at 2018-01-28 13:13:48:000

Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 1.64% to 13.34% Gains To January, 2019 Four of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

A Want-To-Buy List For My 91 Stock Portfolio

via: SeekingAlpha at 2018-01-27 05:33:15:000

I cannot second guess Mr. Market and how it moves a stock price, but I can determine a range of desired yield and what I would be willing to pay if it has a desired dividend growth to go with it. One of my articles here discusses the risk/reward with low low yield to high yield component… read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

via: SeekingAlpha at 2018-01-26 13:01:52:000

Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-01-26 08:01:14:000

Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

CytomX - Augmenting Antibodies Across Indications

via: SeekingAlpha at 2018-01-26 07:26:39:000

Introduction Avid readers will have noticed by now that I have a knack for so-called " platform companies" in the biotechnology sector which, rather than giving multiple targets a relatively random "shot", offer a coherent and potentially disruptive approach towards drug design. Successful … read more...

Medicines Company continues inclisiran-stoked rally, shares ahead 8%

via: SeekingAlpha at 2018-01-24 10:48:17:000

The Medicines Company ( MDCO +8.4% ) adds to its recent up move on almost double normal volume. Shares have rallied 36% this week. More news on: The Medicines Company, Amgen Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Medicines Company continues inclisiran-stoked rally, shares ahead 8%

via: SeekingAlpha at 2018-01-24 10:48:17:000

The Medicines Company ( MDCO +8.4% ) adds to its recent up move on almost double normal volume. Shares have rallied 36% this week. More news on: The Medicines Company, Amgen Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Medicines Company continues inclisiran-stoked rally, shares ahead 8%

via: SeekingAlpha at 2018-01-24 10:48:17:000

The Medicines Company ( MDCO +8.4% ) adds to its recent up move on almost double normal volume. Shares have rallied 36% this week. More news on: The Medicines Company, Amgen Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Medicines Company continues inclisiran-stoked rally, shares ahead 8%

via: SeekingAlpha at 2018-01-24 10:48:17:000

The Medicines Company ( MDCO +8.4% ) adds to its recent up move on almost double normal volume. Shares have rallied 36% this week. More news on: The Medicines Company, Amgen Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Medicines Company continues inclisiran-stoked rally, shares ahead 8%

via: SeekingAlpha at 2018-01-24 10:48:17:000

The Medicines Company ( MDCO +8.4% ) adds to its recent up move on almost double normal volume. Shares have rallied 36% this week. More news on: The Medicines Company, Amgen Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-23 08:46:56:000

Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen's Aimovig successful in late-stage study in treatment-resistant migraine

via: SeekingAlpha at 2018-01-22 16:48:20:000

Amgen (NASDAQ: AMGN ) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen's Aimovig successful in late-stage study in treatment-resistant migraine

via: SeekingAlpha at 2018-01-22 16:48:20:000

Amgen (NASDAQ: AMGN ) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen's Aimovig successful in late-stage study in treatment-resistant migraine

via: SeekingAlpha at 2018-01-22 16:48:20:000

Amgen (NASDAQ: AMGN ) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen's Aimovig successful in late-stage study in treatment-resistant migraine

via: SeekingAlpha at 2018-01-22 16:48:20:000

Amgen (NASDAQ: AMGN ) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen's Aimovig successful in late-stage study in treatment-resistant migraine

via: SeekingAlpha at 2018-01-22 16:48:20:000

Amgen (NASDAQ: AMGN ) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments. More news on: Amgen Inc., Healthcare stocks news, Read more … read more...

Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

via: PR Newswire at 2018-01-22 16:30:00:000

THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previ… read more...

Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

via: PR Newswire at 2018-01-22 16:30:00:000

THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previ… read more...

Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

via: PR Newswire at 2018-01-22 16:30:00:000

THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previ… read more...

Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

via: PR Newswire at 2018-01-22 16:30:00:000

THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previ… read more...

Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

via: PR Newswire at 2018-01-22 16:30:00:000

THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previ… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2018-02-14 2018-03-08 2018-02-15 2017-12-12 1.32 Dividend income Q
2017-11-16 2017-12-08 2017-11-17 2017-10-24 1.15 Dividend income Q
2017-08-15 2017-09-08 2017-08-17 2017-07-28 1.15 Dividend income Q
2017-05-15 2017-06-08 2017-05-17 2017-03-07 1.15 Dividend income Q
2017-02-13 2017-03-08 2017-02-15 2016-12-20 1.15 Dividend income Q
2016-11-14 2016-12-08 2016-11-16 2016-10-14 1.0 Dividend income Q
2016-08-15 2016-09-08 2016-08-17 2016-07-22 1.0 Dividend income Q
2016-05-13 2016-06-08 2016-05-17 2016-03-02 1.0 Dividend income Q
2016-02-11 2016-03-08 2016-02-16 2015-12-15 1.0 Dividend income Q
2015-11-12 2015-12-07 2015-11-16 2015-10-14 0.79 Dividend income Q
2015-08-13 2015-09-08 2015-08-17 2015-07-28 0.79 Dividend income Q
2015-05-12 2015-06-05 2015-05-14 2015-03-04 0.79 Dividend income Q
2015-02-10 2015-03-06 2015-02-12 2014-12-17 0.79 Dividend income Q
2014-11-10 2014-12-05 2014-11-13 2014-10-17 0.61 Dividend income Q
2014-08-12 2014-09-05 2014-08-14 2014-07-25 0.61 Dividend income Q
2014-05-13 2014-06-06 2014-05-15 2014-03-05 0.61 Dividend income Q
2014-02-11 2014-03-07 2014-02-13 2013-12-13 0.61 Dividend income Q
2013-11-12 2013-12-06 2013-11-14 2013-10-16 0.47 Dividend income Q
2013-08-14 2013-09-06 2013-08-16 2013-07-26 0.47 Dividend income Q
2013-05-14 2013-06-07 2013-05-16 2013-03-06 0.47 Dividend income Q
2013-02-11 2013-03-07 2013-02-13 2012-12-13 0.47 Dividend income Q
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX